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INTRODUCTION:
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous  system  (CNS)  characterised  pathologically  by  inflammation, 
demyelination  and  variable  degrees  of axonal  loss  and  gliosis.  Remyelination, 
axonal  and  synaptic  plasticity  have  been  identified  as  mechanisms  underlying 
functional recovery. MS typically follows a chronic course, in the sense that new 
episodes or steady progression are the rule.  Currently radiological surrogates of 
inflammation,  demyelination  and  axonal  loss  are  available,  but  these  correlate 
only  modestly  with  the  development  of cumulative  disability.  In  this  thesis, 
potential brain specific protein (BSP) markers for these pathological processes are 
identified and compared to existing magnetic resonance (MR) markers.
OBJECTIVES:
Levels  of  the  nervous  system  proteins  S100B  (astrocytic  activation),  glial 
fibrillary acidic protein (GFAP; astrogliosis), neurofilaments (axonal marker) and 
ferritin (microglial  activation)  and other inflammatory markers  (i.e.  anti-myelin 
antibodies)  were  measured.  These  values  were  correlated  with  both 
histopathological  measurements  in  post-mortem  specimens  and  MR  imaging 
measures in patients with MS. Histology and immunochemistry of tissue sections 
characterised  normal  and  pathological  CNS  and  localized  the  extent  of 
demyelinating plaques.
2METHODS:
Subiects/Specimens
Sera/plasma and cerebrospinal fluid (CSF) from various cohorts of patients with 
MS or other neurological diseases and blood samples from healthy subjects were 
stored at -80°C. CSF of subjects with demyelinating diseases obtained from the 
Stockholm Optic Neuritis study and the Copenhagen intravenous vs. oral steroid 
trial; sera/plasma from subjects who participated in the primary progressive (PP) 
MS  phase  II  trial  of  IFNP-la  and  clinically  isolated  syndrome  (CIS)  natural 
history study, Institute of Neurology (ION), United Kingdom, were analyzed for 
various BSP.  Prospective collection of fresh post mortem brain specimen (within 
24 hours of death) from MS brain bank at Charing Cross was used for in ex-vivo 
studies.  Cerebrospinal  fluid  and  bloods  of individuals  with  other  neurological 
diseases  (OND)  from  ION  served  as  controls.  Full  patient consent  and  ethical 
approval were obtained.
Laboratory techniques:
Existing  in-house  ELISAs  allowed  ferritin  (microglial  activation;  Keir  et  al., 
1993), S100B for astrocytic activation (Green et al.;  1997), neurofilament heavy 
chain  phosphoforms  and  GFAP  to  be  quantified.  Anti-myelin  antibodies  were 
measured by western blotting by collaborators  in Innsbruck.  Tissues  from post­
mortem specimens were homogenized, and the supernatant measured for the BSP 
described above.  Levels of the BSP proteins in the supernatants were compared
3with quantitative histopathological variables that have been established to assess 
the various pathological processes highlighted above.
ANALYSIS TECHNIQUES
The body fluid markers measured were correlated with MRI and clinical findings; 
Kurtzke’s  Expanded  Disability  Status  Scale  (EDSS).  Post  mortem  specimens 
studied were correlated with histopathology.
OUTCOMES
In  MS  disease  mechanisms  are  complex,  and  as  yet  no  surrogate  marker 
adequately  account  for  disability.  In  this  thesis,  various  fluid  markers  were 
combined with clinical and neuroradiological findings,  in order to better predict 
disease  progression.  This  is an important aim  in that  it may allow us  to target 
therapies to patients with more severe disease and a protein marker may prove 
useful as a surrogate outcome measure in MS treatment trials.
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11Description of Thesis
The thesis is divided into four parts.
Part 1  gives an introduction to optic neuritis and multiple sclerosis, and describes 
the immunology that we understand to date. The roles of surrogate makers and the 
brain specific proteins investigated in this thesis are elaborated.
Part 2 comprises of three studies; the aim of the first study is to evaluate the levels 
of BSP markers in demyelinating diseases. The second study sets out to confirm 
the  findings from the first study and to determine whether one or more protein 
markers may be useful  surrogate marker(s) i.e. predict clinical outcome.  Lastly, 
comparison  is  made  between  the  immunological  markers  studied  with 
histopathology in post-mortem multiple sclerosis brain.
Part 3  answers two important questions, which as yet, have not been answered. 
Firstly, whether serum S100B is raised in patients with PPMS. Of note, levels of 
serum S100B has been studied in patients with relapsing-remitting and secondary 
progressive multiple sclerosis.  Secondly, to confirm the exciting and promising 
findings by Berger et al.  (2003) as to whether anti-myelin antibodies can predict 
conversion to clinically definite (CD) MS.
The final part consists of a summary of the principle findings and the conclusions 
of the thesis.
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23CHAPTER 1
Optic Neuritis, Clinically Isolated Syndrome and Multiple Sclerosis
1.1  Optic Neuritis
1.1.1  Introduction
Optic neuritis  (ON)  is a relatively common  condition  -  the  annual  incidence  is 
about 5:100 000 person-years (Rodriguez et al.,  1995), and it typically involves 
the young adult population. It typically affects Caucasians and females more than 
males. It may develop at any age though its first onset is rare in children and the 
elderly.  The  usual  age  at presentation  is between  20  and 40  years.  In  the  vast 
majority of cases ON is self-limiting with good functional recovery.
1.1.2  Aetiology
The aetiology of ON is unknown. It is considered a complex disorder with genetic 
susceptibility that interacts with an environmental trigger. Although it is claimed 
to  be  immune  mediated,  with  evidence  of autoimmunity  there  is  evidence  to 
support infection as an important trigger.
1.1.3  Differentia] Diagnosis
In the past, ON was thought only to arise in isolation but more recent long-term 
studies have revealed, that in at least 60% of cases it is an early manifestation of 
MS.  Other  conditions  that  it  can  be  associated  with  ON  are  Lyme  disease,
24systemic  lupus  erythematosus,  Behcet’s  disease,  syphilis,  sarcoidosis, 
toxocariasis,  toxoplasmosis  and histoplamosis.  Isolated  ON  over the  age  of 50 
years becomes increasing difficult to distinguish from ischaemic optic neuropathy 
(Rizzo and Lessell, 1991).
1.1.4  Clinical Manifestation
Typically, it manifests as an acute loss of vision or impaired vision, which often 
becomes  apparent on waking from  sleep.  The  defect is progressive  over a  few 
days to 2 weeks. Unilateral involvement is common and the less common bilateral 
disease is seen typically in children following a viral infection (Kriss et al.,  1988; 
Morales et al., 2000). Pain on movement of the affected eye is reported in 92% of 
cases (Foroozan et al., 2002). Mild tenderness around the globe either just before 
or at onset may be present and this can occasionally be distressingly severe and 
accompanied by generalized headache. Pain is also significantly more common in 
retrobulbar  neuritis,  where  there  is  no  abnormality  of the  optic  disc  (Lepore, 
1991).  Painless  ON  is  less  likely  to  be  associated  with  the  subsequent 
development of MS.
Ninety percent of patients with  ON  complain of visual  loss  which varies  from 
minor  blurring  to  blindness  in  the  affected  eye.  Photophobia  and  bright  dots 
(phosphenes)  on  eye  movement  might  be  present.  In  1889,  Uthoff described 
transient blurring of vision following exercise or elevated body temperature. This 
phenomenon is not uncommon in early MS and often noted during the recovery
25phase rather that at onset. The mechanism underlying Uthoffs is a temperature 
dependent intermittent conduction block as a result of a reduced safety factor of 
conduction  in  the  affected  nerve.  It  is  a  good  indicator  that  the  underlying 
pathology is demyelinating.
Progressive deterioration of visual acuity after 2 weeks is uncharacteristic of ON 
and  should  raise  doubts  about the  diagnosis.  In  addition,  improvement usually 
begins within the first month of onset.
1.1.5  Clinical Findings
On examination, reduced visual fields, contrast sensitivity and colour perception 
are  typically  present  in  the  affected  eye.  The  visual  field  defect  is 
characteristically a central  or paracentral  scotoma.  A relative  afferent pupillary 
defect  or  Marcus  Gunn  phenomenon  or  an  afferent  pupillary  defect  is  often 
present and this is due to a lesion in the afferent limb of the pupillary light reflex.
The  term  retrobulbar ON  is  diagnosed  when  the  optic  disc  appears  normal  on 
opthalmoscopic  examination because  the  site  of injury  is posterior to the  optic 
nerve head. This seems to be the case in about two-thirds of affected eyes (Optic 
Neuritis  Study Group  1991).  If the  optic  disc  is  swollen,  this  is  referred to  as 
papillitis and indicates that lesion is in the anterior part of the optic nerve. Optic 
atrophy can occur at a later stage independent of the site of lesion.
261.1.6  Prognosis
Partial to complete remission of sight is almost an invariable feature and occurs in 
greater than 90% of cases after the initial attack. The initial phase of recovery is 
rapid, averaging from 3-5 weeks. Improvement in vision is seen up to a year after 
the acute episode. Of note remyelination can continue for up to 2 years but it is 
not usually associated with functional improvement of vision.
Although most patients recover well from ON, vision after ON can vary greatly 
during the day and from one day to the next, and might deteriorate in situations 
associated with an increase in body temperature such as a hot bath, hot meal and 
exercise (Uthoff s phenomenon). Pulfrich’s phenomenon, which is misperception 
of the  trajectory of moving objects,  that is  an object moving in  2D appears  to 
move in 3D, is occasionally noted. Persistent subtle impairment of colour vision, 
contrast  sensitivity,  depth  perception  and  cortical  evoked  potential  latency 
changes are nearly always demonstrable.
1.1.7  Treatment
The Optic Neuritis Treatment Trial (ONTT) has documented that ON can recur in 
20% of affected eyes,  17% of fellow eyes and in 30% for either eye (Foroozan et 
al,  2002).  The prognosis merely confirms that ON is a common condition and 
can often recur, and that there should be a high index of suspicion for MS in view 
of the fact that at least 60% of cases would subsequently develop the condition.
27The  North  American  Optic  Neuritis  Treatment  Trial  comprised  457  patients 
randomized  to  treatment  with  high-dose  intravenous  methylprednisolone,  oral 
prednisolone or oral placebo (Beck et al,  1992). It was suggested that high-dose 
intravenous methylprednisolone increased the rate of recovery but not the ultimate 
visual outcome.  The efficacy of treatment with oral prednisolone did not differ 
from placebo.
Post-hoc subgroup analyses of the ONTT also suggested that patients who were 
treated with oral predisolone  alone had a higher rate  of recurrent ON,  whereas 
patients treated with methylprednisolone were less prone to develop MS the first 2 
years after treatment (Beck et al.,  1992;  1993;  1995). These findings have been 
questioned because assessment of the risks of recurrent ON and of developing MS 
were not primary aims of the trial (Silberberg, 1993; Goodin, 1993).
In  the  UK,  the  Association  of  British  Neurologists’  guidelines  recommend 
disease-modifying drugs  only in established MS,  which  is clinically active,  i.e. 
patients  should have  had at  least two  significant relapses  in  the preceding two 
years.  Repeat  imaging of patients with CIS could establish earlier diagnosis of 
multiple sclerosis by using the new McDonald criteria (McDonald et al., 2001). In 
some  patients,  this  early  diagnosis  will  enable  a  more  informed  discussion  of 
diagnosis and prognosis and possibly treatment in the future.
28Figure  1.1  Recommended treatment for optic neuritis in adults based on the 
results of the ON treatment trial (Hickman et al., 2002).
Optic neuritis
Unilateral ON  Bilateral ON
1   1   1
MRI brain offered
I   ^ ----------------------------------------1
Normal  Abnormal
1 ________________ I
No treatment  Intravenous Methylprednisolone
lg/kg/day for 3 days
Qualification: The three-year and five-year data from the ONTT however has 
negated this result (Beck et al., 1992; 1993; 1995).
291.2  Clinically Isolated Syndrome
A clinically isolated syndrome (CIS) can be defined as a single focal or multifocal 
event  of acute  onset  in  the  CNS  suggestive  of demyelination.  The  presenting 
attack may be in the optic nerve, brain stem or spinal cord. Although some CIS 
are self-limited, others are the first clinical manifestation of MS.
1.3  Multiple Sclerosis
An episode of ON increases the risk of developing CDMS, which by definition 
requires at least two demyelinating events, separated by time and space. MS is the 
commonest  cause  of neurological  disability  in  the  UK  in  young  adults  with  a 
prevalence of 1  per 1000 and shares similar epidemiological profiles with ON. It 
is a disease of the CNS beginning most often in late adolescence and early adult 
life and usually expressing itself by discrete and recurrent attacks of optic nerve, 
spinal cord, brainstem, cerebellar and cerebral dysfunction.
1.3.1  Natural History
At its onset, MS can be clinically categorized as either relapsing-remitting (RR) 
MS,  observed  in  85-90%  of patients,  or PPMS.  Relapses  or  ‘attacks’  typically 
present  subacutely,  with  symptoms  developing  over  hours  to  several  days, 
persisting for several days or weeks, and then gradually abating.
The outcome of patients with RRMS is variable. About 50% of all MS patients 
who are untreated will require the use of walking aid within 10 years after clinical 
onset (Weinsehnker, 1994). Clinical predictors of a more rapid deterioration are:
301.  Increased attack frequency and poor recovery in the first years of clinical 
disease
2.  Progressive motor onset as opposed to remitting sensory symtoms or ON
3.  Older age/male rather than younger age/female
4.  Polysymptomatic presentation
5.  Multiple MRI lesions, particularly those that gadolinium-enhance1  on the 
first MRI scan.
About  40%  of patients  with  RRMS  develop  a  progressive  neurodegenerative 
secondary disorder related to the chronic CNS inflammation, known as secondary 
progressive  (SP)  MS.  There  are  fewer  gadolinium-enhanced  lesions  and  a 
decrease  in  brain  parenchymal  volume  with  SPMS  (Khoury  et  al.,  1994). 
Furthermore responsiveness to immunotherapy at this stage decreases with time.
The  primary  progressive  form  of MS  is  characterized  from  the  onset  by  the 
absence  of acute  attacks  and  instead  a gradual  clinical  decline.  This  disease  is 
associated with a lack of response to any form of immunotherapy (Hohol et al, 
1999).
1.3.2  Aetiology
The cause of MS, like ON, is unknown. In the 19th century, Charcot described the 
disease as sclerose en plaques. The plaques are damaged oligodendrocyte myelin
1  Gadolinium-enhancement is consistent with acute flux of activated, autoreactive T cells into the 
CNS causing a blood brain barrier breakdown which may be associated with clinical events.
31complexes. Typically, multiple plaques are seen on conventional MRI and biopsy 
samples, and clinically what determines whether or not a lesion causes symptoms 
is  the  size and location  of the  lesion.  For example  brainstem  lesions  are more 
likely to causes symptoms than lesions in the periventricular white matter of the 
cerebral hemispheres. In Chapter 2, the current consensus that MS is an immune- 
mediated condition is discussed further.
1.3.3  Diagnosis
The criteria for diagnosing MS have been standardised. Generally there should be 
at least two neurological events. However, the application of serial MRI findings 
allows one to make the  diagnosis after one clinical  event,  for example after an 
episode of ON, provided one still satisfies criteria for dissemination of disease in 
time and space (Table  1.2). The 2 types of diagnostic criteria incorporated in this 
thesis  are  those  designed  by  the  Poser  committee  (Poser  et  al.,  1983)  and 
McDonald (McDonald et al, 2001) and international panels.
The Poser criteria, published in 1983 were standardised for epidemiological 
studies and therapeutic trials have been widely incorporated in clinical practice. 
These criteria were designed to incorporate CSF analysis2 and results of evoked 
potentials (Poser et al.,  1983) (Table 1.3).
2 Cerebrospinal fluid examination is of prognostic value. About 95% of patients with CDMS have 
locally  synthesized  oligoclonal  IgG  resulting  from  clonal  production  of  IgG  by  activated  B- 
lymphocytes and plasma cells within the central nervous system (Figure 1.4).
32The recently proposed McDonald criterion is a modification of these criteria and 
incorporates MRI findings (McDonald et al.,  2001).  MRI changes have become 
increasingly important as a prognostic tool in patients presenting with clinically 
isolated syndromes such as ON. MRI studies may show swelling and high signal 
lesion in the involved optic nerve (Figure  1.2).  Approximately 50% of patients 
with 3 or more lesions in the cerebral white matter on MRI will go onto develop 
CDMS (Figure 1.3). In contrast 16% of those with ON and normal MRI scan will 
develop CDMS.
33Table 1.1  Recent studies looking at subsequent risk of development of multiple 
sclerosis in patients presenting with CIS
Study Results Comments
Dalton et al. 21% patients had MS at 3 Using new McDonald
2002 months, 48% at 1  year, criteria to patients with
58% at 3 years clinically isolated 
syndrome
Tintore et al. 37% had MS at 1  year, 80% Studied a total of 139
2003 who fulfilled new patients with clinically
McDonald criteria had isolated syndrome, and
second clinical attack in used new McDonald
mean follow-up 49 months. criteria
Brex et al. 88% with abnormal MRI at The increase in MRI
2002 onset had MS after a mean lesion load over 5 years
of 14.1 years. correlated with long term 
disability
Frederiksen et al. 29% had MS at mean All the patients who
1992 follow-up of 27 months. developed MS had lesions 
on MRI at onset
34Table 1.2 New MS Diagnostic Criteria
CLINICAL OBJECTIVE ADDITIONAL REQUIREMENTS
ATTACKS LESIONS TO MAKE DIAGNOSIS
None;  clinical  evidence  will  suffice
2 or more 2 or more (additional  evidence  desirable but must 
be consistent with MS)
Dissemination in snace bv MRI 
or  positive  CSF  and  2  or  more  MRI
2 or more 1 lesions consistent with MS
or  further  clinical  attack  involving
different site
I 2 or more
Dissemination in time by MRI 
or second clinical attack 
Dissemination in SDace bv MRI 
or  positive  CSF  and  2  or  more  MRI
1
1
lesions consistent with MS
monosyptomatic AND
Dissemination in time by MRI 
or second clinical attack 
Positive CSF 
AND
Dissemination in snace bv MRI evidence 
of 9 or more T2 brain lesions
0 1 or 2  or more cord lesions or 4-8  brain
progression and 1  cord lesion
from onset or positive VEP with 4-8 MRI lesions 
or positive  VEP with  less than 4 brain 
lesions plus 1  cord lesion 
AND
Dissemination  in  time  by  MRI  or 
continued progression for 1  year
35Table 1.3  The Poser criteria for MS
Category Attacks  Clinical 
Evidence
Paraclinical
Evidence
CSF
A Clinically Definite (CD)
CD MS Al 2 2
CD MS A2 2 1 and 1
B Laboratory-supported Definite (LSD)
LSD MSB1 2 1 or 1 OCB
LSD MS B2 1 2 OCB
LSD MS B3 1 1 and 1 OCB
C Clinically Probable (CP)
CP MS Cl 2 1
CP MS C2 1 2
CP MS C3 1 1 and 1
D Laboratory-supported Probable (LSP)
LPMS D1 2 OCB
OCB = local synthesis oligoclonal band
36Figure 1.2  Acute right optic neuritis showing high signal lesion in the optic 
nerve on fast spin echo (Courtesy of Dr Simon Hickmann, NMR Unit, IoN).
37Figure 1.3  Abnormal T2 weighted MRI image of patient with multiple sclerosis 
Arrows indicate plaques (Courtesy of Dr Gerard Davies, NMR Unit, IoN).
38Figure 1.4  Isoelectric focusing to reveal oligoclonal IgG production in CSF. 
The upper two lanes are paired serum and CSF samples from a patient without 
MS.  They  show  a  normal  or  polyclonal  pattern.  In  the  lower  pair  there  are 
numerous  IgG bands visible  in the CSF lane that are not present  in the  serum 
sample. This type of distribution indicates the intrathecal synthesis of oligoclonal 
IgG bands that is observed to occur in greater than 95% of patients with multiple 
sclerosis.
Serum -ve
CSF -ve
c
Serum -ve
CSF +ve
C
391.3.4  Epidemiology
MS  is thought to originate  in Europe where  it remains most frequent.  Kurtzke 
(1993b) suggested that MS originated in Scandinavia in the  18th century and that 
the  disease  spread  across  the  Baltic  States  and  Northern  Europe  including the 
British Isles over the next century.  At a later stage, the disease was thought to 
spread to North America, Australasia, South Africa and Italy.
The hypothesis that certain racial groups are susceptible to MS  is based on the 
epidemiology  of  MS.  Geographically  MS  describes  3  frequency  zones.  High 
frequency  areas  (prevalence  30+  per  100  000)  now  comprise  most  of Europe, 
Israel,  Canada,  northern  US,  southeastern  Australia,  New  Zealand  and 
easternmost  Russia.  Medium  frequency  areas  include  southern  US,  most  of 
Australia, South Africa, the southern Mediterranean basin, Russia into Siberia, the 
Ukraine and parts of Latin America. Low prevalence rate (under 5 per  100 000) 
are  found  in  the  rest  of Asia,  Africa  and northern  South  America  (Compston, 
1998).
Migrants from high to low risk areas retain the MS risk of their birthplace if at 
least  age  15  years  at  migration.  Those  migrating  from  low  to  high-risk  areas 
increase their risk beyond that of their native country.  Swingler and  Compston 
(1986)  correlated the  distribution  of MS  in the  UK with regional  variations  in 
population gene frequency and concluded that a frequency gradient exists which 
correlates with a genetic cline marked by HLA-DR2 susceptibility allele.
401.3.5  Genetics
Familial incidence is low but several times higher than chance expectancy.  The 
risk of the disease in the siblings of affected individuals is 3-5%. The importance 
of genetic factors in accounting for this increased risk is confirmed by the results 
of twin and adoption studies (Mumford et al,  1992; Robertson et al,  1997).
Increased susceptibility to  MS  is  genetically linked with the immune molecule, 
MHC class II (Sawcer et al,  1996; Haines et al,  1996; Ebers et al,  1996). The 
Genetic  Analysis  of  Multiple  Sclerosis  in  Europeans  (GAMES)  (Sawcer  and 
Comspton,  2003)  suggests  that  there  is  a  polygenic  mode  of inheritance.  The 
histocompatibility (HLA) antigens  found more frequently in the  MS population 
are HLA-DR2, -DR3, -B7 and -A3.  The genes that confer susceptibility to MS 
are the MHC encoded on chromosomes 6q21  and  17q22 (Sawcer and Compston 
2003; Sawcer et al,  1996).
Other  candidates  have  been  proposed,  including  genes  encoding  the 
immunoglobulin heavy chain,  T cell  receptor beta chain and APOC2,  but none 
has been confirmed (Sawcer et al.,  1996). Evidence for linkage and association to 
the myelin basic protein gene has been reported in a genetically isolated Finnish 
population (Pihlaja et a l, 2003).
In  summary,  what  has  become  clear  is  that  MS  represents  a  complex  genetic 
disease with no clear mode of inheritance.
411.3.6  Genes or Germs?
It may be postulated that as populations emerged out of Africa 30,000 to 50,000 
years ago,  exposure to new microbes resulted in population of individuals with 
combinations of different genes. The latter provided resistance to novel infectious 
agents, and when populations came randomly together, this resulted in a hyper- 
responsive immune system,  with subsequent autoimmune disease.  MS therefore 
may be a price an individual pays for protection of the general population. This is 
analogous to sickle cell and thalassaemia traits (Compston et al.,  1998).
1.3.7  Clinical Manifestation
The first attack of this demyelinating disease usually occurs without warning and 
may be  mono-  or poly-symptomatic.  The  commonest presenting  symptoms  are 
monocular  visual  loss,  diplopia,  vertigo,  facial  weakness  or  numbness,  ataxia, 
nystagmus and weakness or numbness of a limb. Remission after the first attack is 
to be expected and recurrence represents recrudescence of earlier lesions or the 
effects of new ones.
As previously mentioned, the most common clinical subtype is RRMS, and over a 
variable period, the patient becomes increasingly handicapped, and the late stage 
of the disease may be established in 20 to 25  years3. There is no way to predict 
which patients with MS will remain benign over many years. Axonal transection 
seems to begin at disease onset and may be clinically silent during the relapsing-
3 Approximately 90% of RRMS patients (Weinshenker et al., 1989)
42remitting  stage  of  the  disease.  Once  a  threshold  for  axonal  transection  is 
exceeded, MS patients enter an irreversible SPMS stage.
MRI  and  clinical  studies  have  suggested  that  SPMS  is  deterioration  due  to 
degenerative  rather than  inflammatory disease  (Confavreux  et al.,  2000;  2003; 
Brex  et  al.,  2002;  Trojano  et  al.,  2002).  MRI  studies  have  shown  that  while 
measure of the active inflammatory components of the disease such as contrast- 
enhancing  lesions  and  T2  lesions  correlate  with  disease  course  over  the  early 
phase of the disease, the correlation during the progressive phase is poor (Brex et 
al.,  2002).  Clinical  studies  have  indicated  that  the  extent  of  inflammatory 
demyelination and tissue damage may influence the time to an EDSS score of 4 
(see Table  1.4), neurodegenerative mechanisms may likely contribute to neuronal 
decline at more severe stages of the disease (Confavreux et al., 2000; 2003).
In terms  of clinical  outcome  measures,  this  thesis  has  used the  changes  in the 
Kurtzke  Expanded Disability  Status  Scale  (EDSS)  (Table  1.4)  (Kurtzke,  1983) 
which  is  user-friendly  (Kurtzke,  1955),  reproducible  (Kurtzke,  1955),  and 
applicable to all patients (Kurtzke and Berlin,  1954; Kurtzke,  1961).  It is widely 
believed that the EDSS is an impairment scale in its lower range and a disability 
scale  in  its  upper  range  (Sharrack  and  Hughes,  1996).  Nonetheless,  it  is  not 
perfect and the well-recognized disadvantages of EDSS are the poor assessment 
of cognition,  upper  limb  function  and  quality  of life  (Hobart  et  al.,  2000).  In 
addition,  previous  reliability  studies  of EDSS  have  generated  variable  results.
43This inconsistent reliability may reflect the different number of raters used, their 
level of training or expertise, or the sample size. There is no absolute guideline for 
this variable and it has been recommended that raters of Kurtzke scales should be 
trained (Lechner-Scott et al.,  1997).
Due to criticism of the EDSS, in 1994, the MS functional score (MSFC) (Cutter et 
al.,  1999)  was  developed  and  includes  quantitative  tests  of leg  function,  arm 
function  and  cognitive  function.  However,  the  study by  Ozakbas  et al.  (2004) 
comparing the 2 clinical scales concluded that EDSS is still more useful for daily 
routine  practise  because  the  EDSS  is  more  sensitive  in  identifying  changes  in 
functions, and that MSFC is a time consuming process.
Recently,  Roxburgh  et  al.  (2005)  have  devised  an  algorithm;  the  Multiple 
Sclerosis Severity Score (MSSS), which corrects EDSS for duration to compare 
an individual’s disability with the distribution of scores in cases having equivalent 
disease duration.  This method has been  shown to be  more powerful  than other 
tests for detecting different rates of disease progression.
44Table 1.4 Kurtzke’s Expanded Disability Status Scale (EDSS)
0  = Normal neurological examination (all FS normal, mild cerebral signs acceptable)
1.0  = No disability, minimal signs in one FS
1.5  = No disability, minimal signs in more than one FS
2.0  = Minimal disability in one FS
2.5  = Minimal disability in two FS
3.0  = Moderate  disability  in  one  or  mild  disability  in  up  to  4  FS  though  fully
ambulatory
3.5  =  Fully  ambulatory  but  with  a  moderate  disability  in  one  FS  or  2  others;  or 
moderate disability in 2 FS; or mild disability in 5 FS
4.0  =  Fully ambulatory without aid; self-sufficient; up and about 12 hours a day despite 
relatively  severe  disability  in  one  FS  or  combination  of exceeding  the  limits  of the 
previous step. Able to walk without aid or rest for 500m.
4.5  =  Fully ambulatory without aid; up and about much of the day; may otherwise have 
some limitation of full activity or require minimal assistance. Able to walk without aid or 
rest for 300m.
5.0  =  Ambulatory without aid or rest for 200m; disability severe enough to impair full 
daily activities.
5.5  =  Ambulatory without aid or rest for  100m; disability severe enough to preclude 
full daily activities.
6.0  =  Intermittent or unilateral constant assistance required to walk 100m.
6.5  =  Constant bilateral assistance to walk 20m without rest.
7.0  =  Unable  to  walk  5m  even  with  aid.  Essentially  restricted  to  a  wheelchair. 
Transfers alone.
7.5  =  Unable to walk more than a few steps. May need aid with transfers.
8.0  =  Restricted to bed or perambulated in wheelchair. Generally has effective use of
arms. Out of bed for much of the day.
8.5  =  Essentially restricted to bed for much of the day. Retain some self-care  functions.
9.0  =  Helpless bed patient; can communicate and eat.
9.5  =  Totally helpless, unable to communicate effectively or eat/swallow.
10.0=  Death due to MS.
451.3.8  Investigations
1.3.8.1  MRI
MRI is a sensitive imaging technique. Brain MRI (T2 weighted) in MS typically 
shows  periventricular  high  signal  abnormalities;  lesions  may  enhance  using 
gadolinium-DTPA.  Areas  thar  are  preferentially  affected  areas  include  the 
paraventricular,  deep  and  subcortical  white  matter of the  cerebral  hemispheres, 
the  optic  nerve  and  anterior  visual  pathways,  corpus  callosum,  brainstem, 
cerebellum and the spinal cord. The white matter lesions are most apparent using 
the FLAIR (Fast Fluid-Attenuated Inversion Recovery) sequence which increases 
the sensitivity to 98%.
Clinically  silent  lesions  are  common.  Asymptomatic  cord  lesions  have  been 
identified in one-third of patients with clinically isolated optic neuritis (O’Riordan 
et al.,  1998a).  A ten-year follow-up study has shown a strong correlation between 
changes in T2 lesion number-load and EDSS in the first five years, but there was 
a weaker correlation  in  the  second  (O’Riordan  et al.,  1998b).  Lesions  that are 
active, i.e. with acute inflammation, tend to enhance with gadolinium (Grossman 
et al.,  1986; Katz et al.,  1993; Nesbit et al.,  1991; Bruck et al.,  1997; Thompson 
etal.,  1991; 1992).
461.3.8.2 CSF analysis
In about 80% of established cases, the CSF  is abnormal.  There may be  a mild 
mononuclear pleocytosis and a modest increase  in total protein, but the gamma 
globulin fraction is often increased to greater than 12% of the total protein. Over 
95% of patients with CDMS have local synthesis of oligoclonal IgG in the CSF, 
detected by isoelectric focusing (IEF)4.
Other  central  nervous  system  disorders  associated  with  OCB  are  human 
immunodeficiency  virus  encephalitis,  Lyme  disease,  systemic  lupus 
eryhthematosus,  neuroborreliosis,  toxoplasmosis,  sarcoidosis,  vasculitis, 
lymphoma,  paraneoplastic  syndrome,  and  less  frequently  Sjogren  syndrome, 
subacute sclerosing panencephalitis.
1.3.8.3 Neurophysiological studies
Lesions that are not clinically manifest may be revealed by visual, auditory and 
somatosensory evoked potential studies. However they are now rarely needed for 
diagnosis, except in patients presenting with primary progressive MS.
1.3.10  Treatment
1.3.9.1  Disease modifying therapy
4 Oligoclonal bands are IgG resulting from clonal production by activated lymphocytes within the 
CNS. This is not specific for MS and occurs in other inflammatory, infective and demyelinating 
disorders.
47Three  classes  of immunodulating therapies that  impact the  course of early  MS 
have emerged over the last 2 decades: IFN-6; glatiramer acetate which is a MHC- 
binding  peptides  that  engages  the  T-cell  receptor;  and  the  immunosuppresant 
compound Mitoxantrone.
Two forms of recombinant IFN-6, -la (Avonex, Rebif) and -lb  (Betaferon), are 
licensed in Europe for the treatment of patients with RRMS.  Their efficacy has 
been proven in several multicentre, controlled trials (The IFNB MS Study Group, 
1993; Paty and Li,  1993; Jacobs et al,  1996; PRISMS Study Group,  1998). IFN- 
6-lb has also been licensed for the treatment of SPMS. The latter is on the basis 
of a single trial by the European Study Group (1998), which demonstrated a small 
benefit on progressive disability in this subgroup of patients.
Recombinant beta interferons are produced in different cell systems, which result 
in  some  differences  in  their  aminoacid  structure,  molecular  weight,  degree  of 
glycosylation,  and  specific  activity  (tested  against  the  antiviral  activity  of the 
WHO reference standard of human interferon beta) (Revel  and Kalinka,  1997). 
Interferon  beta  has  been  shown  to  reduce  relapse  frequency  and  severity  by 
approximately a third (Jacobs et al.,  1996; PRISMS, 1998).
48The specific mode of action of IFN-6 in MS is unknown. IFNs were initially tried 
in MS for their antiviral effect5  (reviewed in Jacobs and Johnson,  1994) and IFN- 
6  turned  out  to  have  beneficial  effect.  Other  properties  of  IFN-6  are  anti­
proliferative  actions,  although  its  immunomodulatory  effects  such  as  reduced 
transcription of MHC class II molecules are considered more important (Amason 
and Reder, 1996; Yong et al., 1998).
IFN-6 is produced by all  mammalian cells upon stimulation and is encoded by 
single genes.  A myriad of effects of IFN-6 have been described but the relative 
importance of the variety of actions are not well understood, therefore at present 
time, the mechanisms of IFN-6 treatment remain unknown.
1.3.9.2  Symptomatic Treatment
Three  day  or  five  day  courses  of  intravenous  methylprednisolone  have  been 
shown to  speed the recovery of clinical relapses  in MS  (Milligan et al.,  1987). 
Oral  high  dose  methylprednisolone  is  also  used  and  has  been  shown  to  be  as 
effective as intravenous methylprednisolone when given in a three-week tapering 
dose.
Relapses are likely to be caused by the traffic of activated, myelin-reactive T cells 
into the CNS, causing acute inflammation with associated oedema. The ability of 
high dose steroids to improve the symptoms of an MS relapse suggests that the
5  IFNs trigger the synthesis of many host cell protein that contribute to the inhibition of viral 
replication.acute  oedema  and  its  subsequent  resolution  may  partly  underlie  the  clinical 
relapse and remission respectively.
50Chapter 2
Immunology in Clinically Isolated Syndrome and Multiple Sclerosis
2.1  Historical perspective
In  1868, Charcot noted the accumulation of inflammatory cells in a perivascular 
distribution  within  the  brain  and  spinal  cord  white  matter  of  patients  with 
intermittent episodes of neurological dysfunction (Charcot,  1877). This led to the 
term sclerose en plaques disseminees, or MS.
In  1933, Thomas Rivers demonstrated an autoimmune, demyelinating disease in 
mammals  with  immunization  of  the  CNS  myelin  (experimental  autoimmune 
encephalomyelitis, EAE) (Rivers et al,  1933).
In  1948, Elvin Kabat observed an increase in oligoclonal immunoglobulin in the 
CSF of patients with MS that provided further evidence of an inflammatory nature 
of the disease.
Between 1950-2004, at least 30,000 scientific papers on MS have been published.
2.2  Immunology
The hallmark of MS is immune-mediated damage to the oligodendrocyte myelin 
complex in multiple CNS areas, producing plaques, which are often perivascular. 
Although  a  search  for  a  specific  virus  or  antibody  in  MS  has  been  at  best 
inconclusive. Some assume that a viral infection underlies the cause of MS either
51as  the  primary cause  or possibly as  the  trigger that  establishes  the  pathogenic 
cascade in MS6.
Raised serum anti-viral antibodies and viral RNA and DNA have been detected in 
MS  patients  include  measles,  varicella,  mumps,  Epstein-Barr  virus,  MS- 
associated retrovirus, human herpesvirus 6 etc. (Adams and Imagawa,  1962; Ter 
Meulen  and  Stephenson,  1983;  Wandinger  et  al.,  2000;  Dolei  et  al.,  2002; 
Challoner et al., 1995).
The serum in MS shows little change in the total level of immunoglobulins, but in 
most  cases,  circulating  immune  complexes  can  be  found  (Goust  et  al.,  1978). 
There  is,  as  yet,  no  evidence  that  these  can  cause  demyelination,  and 
demyelination is not a feature of circulating immune complex diseases (Lebowitz, 
1983).
2.2.1  Inflammation
Potentially auto-aggressive T-lymphocytes normally occur in the circulation and 
they  are  usually  controlled  by  peripheral  clonal  inactivation  (anergy)  and 
suppression.  However,  in  susceptible  individuals,  an  unknown  environmental 
trigger such as viruses can activate these cells.  Upon activation, T-lymphocytes 
express adhesion molecules and attach to endothelial cells.
6 It could be further argued that the disease is caused by an unknown virus or is an abnormal 
reaction to an unidentified virus.
52Both serum and CSF levels of soluble vascular cell adhesion molecule (VCAM) 
are significantly raised in MS patients during an acute exacerbation compared to 
patients with chronic progressive MS (Matsuda et al.,  1995).  On reencountering 
their  autoantigen  in  the  CNS  these  cells  are  reactivated  and  initiate  a  typical 
cascade of cell-mediated inflammation.
The  perivascular  inflammatory  infiltrates  in  MS  are  mainly  composed  of T- 
lymphocytes,  some  B  cells  and  plasma  cells  and  activated  macrophages  or 
microglia cells. The active lesions are characterised by perivascular infiltration of 
oligoclonal T cells, monocytes with occasional B cells and infrequent plasma cells 
(Prineas and Wright, 1978).
2.2.2  Demyelination
Active  demyelination  in  MS  is  accompanied  by  inflammation.  Although  it  is 
generally believed that inflammation is an obligatory and possible primary feature 
of demyelination in MS,  it has to be  emphasised that in exceptional cases -  in 
particular,  after  profound  immunosuppressive  therapy,  myelin  destruction  may 
proceed in spite of a near lack of lymphocytic infiltration. The latter observations 
implicate  a  role  for  endogenous  glia  (microglia,  astrocytes)  as  sources  of 
mediators.
2.2.3  Axonal Damage
Demyelination with relative preservation of axons and astroglial scarring are the 
pathological  hallmark of MS  lesions.  Acute  axonal  damage  is  found mainly in
53lesions with recent or ongoing demyelinating activity.  This secondary injury to 
the axon may be the result of either (1) T cell cytotoxicity, or (2) the failure of 
local  target-derived  neurotrophic  support  from  death  of  myelinating 
oligodendrocytes.
Axonal  loss  can  apparently  precede  the  onset  of  substantial  demyelination. 
Axonal loss continues within the active margin of older lesions, but it appears not 
to be a feature of inactive chronic lesions. The mechanism by which T cells and 
macrophages  transect  axons  within  the  acute  or  active  chronic  lesion  remains 
unclear.  Instead, acute  inflammatory mediators,  such as proteases,  free radicals, 
cytokines and complement, are more likely to have an effect on axonal integrity. 
Wallerian  degeneration  of  the  distal  portion  of  the  axon  results  in  axonal 
breakdown in about  18  hours,  and these events are most likely triggered in the 
acute lesion (Kapoor et al., 1999; Coleman et al.,  1998).
2.2.4  Remyelination
In  brain  lesions  obtained  during  the  early  course  of  the  disease,  numerous 
oligodendrocytes  may  be  present,  and  such  lesions  may  exhibit  rapid  and 
extensive  remyelination.  Such  lesions,  ‘shadow  plaques’,  represent  the  idea  of 
partial  repair  of an  MS  lesion.  In  some  lesions,  in  particular  at  site  of active 
myelin  destruction,  oligodendrocyte  loss  may  be  minor  and  in  others, 
demyelination may be  associated with extensive  (some  suggest up  to  70%)  or
54complete disappearance of these cells (Wolswijk,  1998). This may be due to lack 
of appropriate trophic factors.
Remyelination  is probably more  effective  in the  early  stages  compared  to  late 
stages, and frequent episodes of demyelination in remyelinated areas may lead to 
progressive destruction of mature oligodendrocytes as well as progenitor cells.
The  mechanism  by  which  the  inflammatory  process  is  subsequently  down 
regulated  is  unclear.  Oligodendrocytes  are  depleted  by  a  cytolytic  mechanism 
(Raine et al., 1998) and apoptosis may be a contributing factor.
2.3  Histopathology
Gross examination of brain tissue of individuals with MS reveals multiple sharply 
demarcated plaques in the CNS white and grey matter with a predilection to the 
optic nerves and white matter tracts of the periventricular regions, brain stem and 
spinal  cord.  Substantial  axonal  injury  with  axonal  transections  is  abundant 
throughout active MS lesions (Trapp et al.,  1998).
Approximately 2% of chronic lesions show evidence of acute myelin destruction 
-   inflammatory  cell  infiltrates  and  fresh  myelin  debris  within macrophages,  as 
well as progressive loss of oligodendroctyes possibly through lytic or apoptotic 
mechanisms and marked axonal pathology. In chronic inactive lesions, low grade
55axonal  degeneration  persists  (Trapp  et  al.,  1998)  and  remyelination  is  often 
present at the lesion margin.
On a cellular level, lymphocytes may be found in normal appearing white matter 
beyond the margin of active demyelination. Macrophages are most prominent in 
the centre of the plaques and are seen to contain myelin and debris.  In chronic 
active  lesions, the  inflammatory cell  infiltrate  is  less prominent and are  largely 
restricted to the rim of the plaque. Many chronic plaques become fully burnt-out 
and  further  immuno-inflammatory  response  is  probably  prevented  by  marked 
gliosis7.
7  Astrocytes  proliferate  within the  chronic  lesions  and become  fibrillary (GFAP),  laying  down 
astrocytic fibres in parallel packed rows known as isomorphic gliosis.Chapter 3
Biological Markers in Multiple Sclerosis
According to the NIH Biomarker Definitions Working Group (1998), a biological 
marker (biomarker) is defined as  *  a characteristic that is objectively measured 
and  evaluated  as  an  indicator  of  normal  biologic  processes,  pathogenic 
processes, or pharmacologic responses to a therapeutic intervention. ’ Surrogate 
endpoint is a biomarker that is expected to predict clinical benefit/harm, or lack of 
benefit/harm,  based  on  epidemiologic,  therapeutic,  pathophysiologic  or  other 
scientific evidence. Such a marker has not yet been met with respect to MS.
Currently  the  most  useful  secondary  outcome  measures  in  clinical  studies 
available in MS are MRI based,  encompassing a number of techniques that are 
sensitive  for,  and  can  measure,  different  components  of MS  pathology  and  to 
detect  clinically  silent  lesions.  The  finding  of  intrathecal  oligoclonal 
immunoglobulin bands  is useful  in clinical practice but the antigen specifity of 
these oligoclonal bands in MS continues to elude investigators.
Thus  there  is  still  a  need  to  develop  well-validated,  reliable,  responsive  and 
acceptable  biomarkers  so  that  the  management  of  patients  with  MS  can  be 
improved. This thesis evaluates possible immunological protein markers found in 
body fluid that may aid  in predicting and monitoring neurological  decline  and 
thus allow the identification of better biomarkers to be explored.
573.1  MRI
MRI is sensitive for detecting MS lesions and correlates well with clinical relapse 
(Smith et al.,  1993; Thompson et al.,  1992; Wiebe et al.,  1992) but only poorly 
with long-term clinical disability as measured by the Kurtzke’s EDSS (Kurtzke, 
1983)  and  limited  ability  to  predict the  eventual  course  of MS  (Filippi  et al.,
1995).
A number of new MRI techniques have been developed to examine brain tissue 
known  to  be  diseased,  but  in  which  T2  lesions  have  not  been  detected.  They 
include  measuring brain  volume,  MR  spectroscopy,  MTR  imaging  and  myelin 
water imaging.
Table 3.1  MRI outcome measures in MS 
Markers of inflammation
New lesion activity (e.g. new T2 lesions, Gd-enhancement)
Burden of disease (e.g. T2 lesion volume)
Markers of  degeneration 
Atrophy (brain and spinal cord)
N-acetyl aspartate (lesions and normal appearing brain tissue)
Black holes on T1 (tissue destruction)
Magnetisation transfer imaging (lesions and normal appearing 
brain tissue)
Myelin water imaging
583.2  CSF Oligoclonal Bands
The  CSF  in  MS  shows  an  increase  in  total  immunoglobulins,  a  k/X,  pattern 
different  from  that  in  plasma,  and  a  number  of  oligoclonal  bands.  These 
oligoclonal  bands  indicate  clones  of antibodies  which  may be  directed  against 
specific  but unidentified  antigens,  and  have  been  demonstrated  in  95%  of MS 
cases by isoelectric focusing (McClean et al.,  1990). They are not specific to MS 
and are found in other CNS inflammatorty and infectious disorders that stimulate 
antibody production in the CNS (Thompson et al., 1979; Salmi et al.,  1983).
3.3  Brain specific proteins
In  this  thesis,  five  different  types  of BSP  are  studied.  Ferritin,  a  marker  of 
microglial activation;  S100B and glial fibrillary acidic protein (GFAP), markers 
of  astrocytic  activation  and  gliosis;  and  two  neurofilament  heavy  chain 
phosphoforms (NfHSM 134 and NfHSM I35), markers of axonal damage or loss. Anti- 
MBP and anti-myelin oligodendroctye glycoprotein (-MOG) are also investigated 
as potential surrogate endpoints.
59Table 3.2 Characteristics of the brain specific proteins
Brain Specific 
Proteins
Localization Functions
Ferritin Oligodendrocytes Iron binding,
(primarily) growth,
? protect against 
oxidative insults
Glial fibrillary Astrocytes Structural
acidic protein
Neurofilament Axons Structural
S100B Astrocytes ? Trophic, 
calcium binding
Myelin basic Myelin Structural
protein
Myelin Myelin Structural
oligodendroctye
glycoprotein
603.3.1  Neurofilaments
Neurofilaments, to date, are one of the more promising axonal markers. They are 
important structural  proteins of the  neuron and are particularly concentrated  in 
large myelinated axons. However they are, only to a minor extent, expressed in 
neural  cell  bodies.  Neurofilaments  are  soluble  lOnm  diameter  triplet  proteins, 
which appear filamentous on electron microscopy and are found in the cytoplasm 
of neurons but not of other cells in the nervous system.
Neurofilaments  have  an  a-helical  rod  domain,  involved  in  the  formation  of 
oligomers, a N-terminal head domain, involved in the regulation of its assembly, 
and a C-terminal tail domain which is the main site for phosphorylation. The latter 
plays a role in protein-protein and protein-organelle interaction (Ching and Liem, 
1998).  The degree of phosphorylation also determines the diameter of an axon 
and the rate of neurofilament transport (Ackerley et al, 2003), i.e. the higher the 
phosphorylation, the broader the diameter (Fuchs and Cleveland,  1998) and the 
slower the transport rates8 (Ackerley et al.,  2000; Sanchez et al.,  2000;  Yabe et 
al., 2001).
Neurofilaments  are  composed  of three  major polypeptides  subunits  known  as: 
neurofilament  light  chain  (NfL)  (molecular  weights:  62kDa),  NfM  or
intermediate  chain  (molecular  weight:  102kDa)  and  heavy  chain  (NfH) 
(molecular weight:  200kDa) (Fuchs and Cleveland,  1998). The length of the C-
8  Neurofilaments  are  transported  through  axons  by  a  process  termed  slow  axonal  transport 
(Ackerley et al., 2003).
61terminal tail determines the differences in molecular mass, and they are so-called 
for their low, middle and high positions on sodium dodecyl sulfate (SDS) gels.
NfL corrects the assembly of neurofilaments and maintains axonal calibre. NfM 
forms  cross-bridges,  stabilizes  filament  networks  and  helps  in  longitudinal 
extension.  NfH  forms  cross  bridges  and  interact  with  microtubules  and  other 
cytoskeletal elements (Al-Chalabi and Miller, 2003).  In recent years it has been 
realized  that  neurofilaments  may  also  contain  the  proteins  alpha-intemexin, 
peripherin, nestin and vimentin. There are also several interesting neurofilament 
associated  proteins  such  as  plectin  and  dystonin  which  appear  to  integrate 
neurofilaments into a functioning network with microtubules and microfilaments.
This thesis concentrates on neurofilament heavy chains, in particular, two heavily 
phosphorylated  phosphoforms:  NfHSM I34  and  NfHSM I35.  The  latter  is  less 
phosphorylated  than  NfHS M 134  (Table  3.4)  (Goldstein  et  al.,  1987a,  1987b; 
Stemberger and Stemberger,  1983). NfH is encoded on chromosome 22ql2.2 and 
consists of 1020 amino acids (Lees et al.,  1988). Up to nine NfH phosphoforms 
has  been  identified  to  date,  and  they  differ  according  to  the  degree  of 
phosphorylation9  (Table  3.4).  So  far however it has  been not been  possible  to 
develop an ELISA that would allow quantification of all NfH phosphoforms.
9 NfH is resistant to protease activity whereas NfL is not (Goldstein et al.,  1987; Schlaepfer et al., 
1985; Wang et al.,  1992)
62Table 3.4 illustrates the nomenclature that has been proposed by Stemberger and 
Stemberger  (1983).  It  is  based  on  the  capture  antibody,  and  is  to  allow 
differentiation of NfH phosphoforms with immunological methods.
Increased  CSF  levels  of the  neurofilament  have  been  reported  in  neurological 
disorders  such  as  Alzheimer’s  disease,  amyotrophic  lateral  sclerosis  (Lou 
Gehrig’s  disease),  giant  axon  neuropathies,  infections  and  autoimmune  CNS 
disease including MS (Rosengren et al,  1999; Holmberg et al.,  1996). It has been 
speculated that the aberrant transport, processing or expression of neurofilaments 
could contribute to neurological disease. Recently point mutations in some of the 
neurofilament proteins have been shown to be causative of certain neurological 
disorders, the best example being certain types of Charcot-Marie-Tooth disease 
(Rao and Nixon, 2003; Al-Chalabi and Miller, 2003)
Axonal loss correlates with permanent neurological disability in chronic relapsing 
experimental allergic encephalomyelitis (CREAE) (Wujek et al, 2002). NfHSM I35 
levels were significantly lower in CREAE when compared with control animals 
(Petzold et al,  2003). Two other groups have confirmed this and have observed 
axonal loss in these animals using immunocytochemical techniques (Wujek et al, 
2002; Baker etal.,  1990].
In relation to demyelinating diseases, several studies have indicated that patients 
with MS have a high concentration of NfL in CSF (Lycke et al,  1998; Semra et
63al.,  2002; Haghighi et al.,  2004; Malmestrom et al.,  2004; Norgren et al.,  2003). 
The increased CSF NfL chain was found in patients with RRMS and correlated 
with disability, exacerbation rate and length of time from the start of the previous 
exacerbations (Lycke et al.,  1996). Malmestrom et al.  (2003) also supported the 
latter findings, indicating continuous axonal damage during the entire course of 
the demyelinating disease with the most profound damage during acute relapses 
(Table  3.3).  The  highest  levels  of NfL  chain appeared  approximately  3  weeks 
after relapse onset (Malmestrom et al., 2003).
In  2002,  two  separate  studies  by  Silber  et  al.  and  Da  Silva  and  Ditto  (2002) 
reported  the  presence  of antibodies  against  NF  proteins  in  CSF  (2002).  High 
levels  of intrathecal  anti-NfL  autoantibodies  were  detected  in  progressive  MS 
patients  compared  to  RRMS  patients,  healthy  controls,  and  those  with  other 
neurological  disorders  (Silber et al,  2002).  The elevated levels of antibodies to 
NfL may be a consequence of ongoing axonal damage, which is further supported 
by a study that in patients with  MS,  CSF concentrations  of NfL correlate with 
clinical disability and recent relapses (Lycke et al.,  1998). In contrast, antibodies 
to NfH did not differ between patients with MS and normal controls (Stefansson 
et al.,  1985), and correlated less well with disease duration and disability.
MR investigations have provided evidence  for axonal damage  in early MS (De 
Stefano et al., 2002). Indeed, axonal loss may be occurring at the time of clinical 
onset  (Fillipi  et  al.,  2003).  The  cause  of  axonal  loss  in  MS  is  still  poorly
64understood. The NfL autoantibody index1 0 was investigated in a group of 51  MS 
patients consisting of 21  RRMS, 20 SPMS and 10 PPMS patients, and was found 
to  correlate  positively  with  measures  of  cerebral  atrophy  as  expressed  by 
parenchymal  and  ventricular  fraction,  while  the  NfH  autoantibody  index 
correlated positively only with the ventricular fraction (Eikelenboom et al., 2003). 
Early  axonal  damage  contributes  to  cerebral  atrophy  and  clinical  disease 
progression  and  provides  further  rationale  for  early  intervention  with 
immunomodulatory MS therapy (Rudick, 1999).
Thus  far,  neurofilament  light  chains  and  autoantibodies  against  neurofilaments 
light and heavy chains have been studied in relation to multiple sclerosis.  This 
thesis explores other phosphoforms, namely neurofilament heavy chain (NfHSM I35 
and NfHSM I34) as potentially useful markers in demyelinating diseases.
10 NfL antibody index is defined as the CSF to serum ratio of NF antibodies divided by the CSF to 
serum ratio of albumin.
65Figure 3.1  Schematic diagram of neurofilament monomers
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663.3.1.1 ELISA method to detect neurofilament heavy chain phosphoforms
A  specific ELISA for measuring neurofilament heavy chain phosphoforms was 
developed by Petzold et al.  (2003).  The 2  subtypes of phosphoforms measured 
were  NfHSM I34,  which  is  highly  phosphorylated,  and  NfHSM I35,  which  is  less 
phosphorylated (Table 3.4). Briefly, microtitre plates were coated overnight with 
lOOpl of mouse monoclonal anti-NfH antibodies (SMI clones 34 or 35) diluted in 
1/5000 in 0.05M carbonate buffer, pH 9.5.The plates were washed with barbitone 
buffer containing 0.1% bovine serum albumin (BSA) and 0.05% Tween 20 (pH 
8.9), and then blocked with 250pl barbitone buffer containing 1% of BSA. 50pl of 
standard, control or CSF samples were added in duplicates with 50pi of sample 
diluent which constituted of 50pl barbitone buffer, 6mM EDTA and 0.1% BSA. 
After incubating at room temperature for an hour and washed,  lOOpl of detector 
antibody:  rabbit polyclonal  anti-NfH  from Affiniti  (Exeter,  UK)  diluted  1/1000 
was  added  then  incubated  for  an  hour  at  room  temperature.  The  wells  were 
washed  then  horseradish  peroxidase  (HRP)-labelled  swine  anti-rabbit  antibody 
diluted  1/1000,  were  added  and  incubated  an  hour  at  room  temperature  then 
washed.  lOOpl TMB substrate was added and incubated in dark then the reaction 
was stopped with50pl 1M hydrochloric acid (HC1) and the absorbance read at 450 
and 750nm. The upper reference value for CSF NfHSM I35 is 0.73ng/mL. None is 
available for CSF NfHSM I34.
67Table 3.3  Neurofilament studies of MS
Year First Author Body
fluid
NF
type
Cohort Observations
1998 Lycke CSF NfL 60 RRMS 
11 healthy control
TNFL in MS 
Correlate with 
disability, relapse rate
2002 Semra CSF NfL 35 MS
(19 PPMS or SPMS, 16 
RRMS)
36 other 
neurological 
diseases
fNFL in SPMS and 
PPMS
Correlate with 
disability
2003 Malmestrom CSF NfL 66 MS
(41  RRMS, 25 SPMS) 
50 healthy control
tNFL in relapse 
RRMS > remission 
RRMS and SPMS. 
Overall fNFL in MS.
2004 Haghighi CSF NfL 47 MS
47 healthy siblings
fNFL in CDMS 
<->NFL in siblings
f = increase; < -►  = no change/constant
68Table 3.4  Nomenclature  and  characteristics  of the  9  types  of NfH
phosphoforms,  the  immunocytochemical  staining pattern,  the  antibody binding 
epitope,  the  antibody  type  and  the  commercial  (Stemberger  monoclonal)  and 
previously published notation for the mouse monoclonal antibodies used in this 
study.
Types of epitopes:
Extensively phosphorylated 
oS®   Phosphorylated
§§§§§  Non phosphorylated
Ab  Antibody
(see next page)
69NfH
phosphoforms
Immunocytochcmical 
staining pattern
Phosphorylation
state
Ab type
NfHSM 1" Neuronal cell bodies, 
dendrites, proximal axons and 
axon-terminal spheroids
ofloflo
IgGl
NfHs'"” Neuronal cell bodies, 
dendrites, many axons and 
some macrophages
W iV
ofloto
IgM
NfHs'" '4 Most axons. m
IgGl
NfHSMl35 Most axons. tctot
SE lo
IgGl
N f H SMI37 Neuronal cell bodies 
subpopulation, dendrites and 
thick axons
sogcg IgM
NfHSM I38 Neuronal cell bodies, 
dendrites and thick axons
g g M
ofloflcj
IgGl
NfHSM I310 Some axons in normal tissue. 
More axons in pathologic 
condition “
IgGl
Neuronal cell bodies with 
dendrites and thick proximal 
axons
m
Ab
cocktail
NfHN EI4 Axons, spiral ganglion 
neurones W
IgGl
703.3.2  S100B
SI00 was originally discovered by Moore in 1965 and derived its name from the 
fact that it is soluble in 100% saturated ammonium sulphate at neutral pH. It is an 
acidic calcium binding protein with molecular weight of 20kDa. It consists of two 
beta subunits and is located in the cytoplasm of astrocytes and is also expressed in 
Schwann cells in peripheral nerve. Today there are more than  16 different SI00 
members and S100B and S100A1 are the most studied (Donato, 2001).
Its function is unknown. S100B is secreted by astrocytes and acts on these cells to 
stimulate  nitric  oxide  secretion  in  an  autocrine  manner  (Adami  et  al,  2001). 
S 100’s  toxic  effects  have  been  suggested to  depend  on  stimulation of calcium 
influx into responsive cells or nitric oxide release from astrocytes (Hu et al., 1996; 
1997).  S100B  release  has  been  shown  to  occur  via  apoptosis.  Due  to  its 
extracellular effects, it has been viewed as a cytokine (Griffin et al.,  1998). It has 
also  been  implicated  in  the  regulation  of (1)  the  dynamics  of the  cytoskeletal 
constitute  (via protein  phosphorylaton)  (2)  cell  cycle  progression  (possibly via 
interactions with transcription factors) and (3) enzymes (Schafer and Heizmann,
1996).
High  concentrations  of  S100B  are  found  in  head  injury,  subarachnoid 
haemorrhage, rapid parenchymal destruction in epilepsy, CJD, acute brain injury, 
compression  of the  spinal  cord  by  tumours,  ischaemic  disorders  and  viral  or 
suspected viral infection (Donato, 2001; Sindic,  1982). Its presence in the CSF is 
due to an immediate release from the cytosol of damaged astrocytes and there is
71then a delayed rise in the serum (on day 2) (Petzold et al., 2003). SI00 may thus 
be an index of CNS injury.
In slowly progressive diseases, S100B might play a different role i.e. modulating 
the inflammatory response through stimulation of inducible nitric oxide synthase 
(iNOS) -  (Donato, 2001; Adami, 2001). Abnormal levels are found in Downs’s 
syndrome  where  its  expression  is  increased  in  astrocytes  and  increases 
progressively  with  age  (Royston  et al,  1999).  It  is  also  present  in  plaques  in 
Alzheimer’s  disease  (Griffm et al.,  1998) -  albeit via an unknown mechanism. 
Studies on S100B and MS have been extensive: Petzold et al. (2003) observed, in 
post-mortem brain homogenates, that S100B is a marker for the relapsing phase 
of MS (higher levels in acute versus subacute plaque).  Furthermore, RRMS had 
higher CSF S100B  levels compared with SPMS  thus  S100B could be useful to 
differentiate between RRMS and progressive MS.
Nonetheless  the  value  of S100B  as  a  marker of disease  activity has  not  been 
established and the results  from several  studies are contradictory (Noppe et al., 
1986; Lamers et al.,  1995, Green et al.,  1997, Malmestrdm et al., 2003).
723.3.2.1 ELISA method to detect S100B
A sensitive and specific in-house ELISA was used for measuring S100B in CSF 
as  described  by  Green  et  al.  (1999).  Ninety-six-well  plates  were  coated  with 
monoclonal  anti-SlOOB  at  a  concentration  of  9.3pg/ml  in  0.05M  carbonated 
buffer, pH 9.5. The plates were washed with 0.67M barbitone buffer containing 
5mM calcium lactate,  0.1% BSA and 0.05% Tween and then blocked with 2% 
BSA for 1  hour and washed again. 50pi of standard, control or CSF samples were 
added in duplicate and 50pl of 0.67M barbitone buffer containing 5mM calcium 
lactate. The plates were incubated at room temperature for  1   hour then washed. 
Rabbit  anti-SlOO  antibody conjugated  with HRP polyclonal  anti-SlOOB  (Dako, 
Copenhagen,  Denmark)  diluted  1/1000  with  incubation buffer  was  added.  The 
plate was incubated for 20 minutes at room temperature in the dark; the colour 
reaction  was  stopped with  50pl  1   M  HC1  and the  absorbance  read  at 450  and 
750nm on a Wallac Victor 2. The antigen concentration was calculated from an 
internal  standard  curve  ranging  from  0.01  to  2.5ng/ml.  The  normal  reference 
range is 0.55ng/mL and less.
73Table 3.5 S100B studies of MS
Year First Author Body fluid Cohort Observations
1979 Michetti CSF 18 MS
11 neurological 
or psychiatric diseases
tSIOOB in acute phase of 
MS
1985 Massaro CSF 10 MS 5 weeks post­
relapse
Peak |S100B in 3rd week 
and detectable in all 5 
weeks
1986 Noppe CSF 535 neurological 
disease: MS, 
encephalitis, stroke, 
tumour compression
<->S100B
1995 Lamers CSF 17 neurological 
disease
|S100B in stroke
1997 Missler Plasma 28MS
(17 relapse 
11  stable)
120 healthy control
fSlOOB in initial 7 days 
after relapse.
<-»S100B 8 to 28 days 
post-relapse.
2002 Petzold CSF
Brain
homogenate
51 MS 
(20RRMS,
21SPMS, 10PPMS)
51 OND
PM brain tissue (12 
MS, 8 control)
TS100B in RRMS and 
acute PM lesions
2003 Malmestrom CSF 66 MS (41  RRMS, 25 
SPMS)
50 healthy control
<->S100B
t  -   increase;  « -►   =  no  change/constant
743.3.3  Glial Fibrillary Acidic Protein
GFAP is an intermediate filament (IF) protein of astroglia discovered in 1969. Of 
note,  IF  proteins  constitute  an  extremely  large  multigene  family  of 
developmentally and tissue-regulated cytoskeleton proteins.
GFAP has a molecular weight of 50kDa, and is 8-9nm long. It is composed of a 
head domain, a central rod domain and a carboxy terminal tail domain.  It is an 
insoluble CNS-derived protein and its assembly is regulated by phosphorylation- 
dephosphorylation of the head domain by altering its charge (Inagaki et al,  1994). 
However, in CSF, it is secreted in its soluble form and is considered a biomarker 
of astrogliosis in neurodegenerative disorders.
Its  function  is  thought  to  be  in  modulating  astrocyte  motility  and  shape  by 
providing structural stability to astrocytic processes. Levels of GFAP are altered 
during  development  and  aging  (Laping  et  al.,  1994;  Gomes  et  al.,  1999).  It 
responds  dynamically  to  neurodegenerative  lesions  and  its  level  is  often 
upregulated after CNS insult. Furthermore, the astroglial response occurs rapidly 
and  can  be  detected  within  an  hour  of a  focal  mechanical  trauma  (Eng  and 
Ghinikar,  1994).  Thus  it  is  useful  as  a  biologic  marker  of  disease  activity, 
reflecting an increasing rate of astrogliosis.
Increased  GFAP  levels  have  been  observed  in  CNS  diseases  such  as  AIDS 
dementia  (Eng  and  Ghinikar,  2000);  brain  infarction  (Aurell  et  al.,  1991);  a
75variety  of viral  infections  and  neuroborreliasis  (Dotevall  et  al.,  1999);  prion 
associated spongiform encephalopathies; inflammatory demyelinating disease and 
neurodegenerative  diseases  such  as  Alzheimer’s  disease  (Eng  and  Ghinikar, 
2000).
As  a nonspecific biomarker of CNS tissue  injury,  GFAP has been noted to be 
upregulated  in MS  (Noppe et al,  1986;  Rosengren et al.,  1995;  Petzold et al, 
2002; Malmestrom et al, 2003; Haghighi et al, 2004) (Table 3.6). Astrocytes are 
perhaps activated in acute MS lesions and participate in gliotic scar formation in 
chronic lesions, revealing information about the ongoing pathologic processes in 
MS.  In  a  study  by  Rosengren  et  al,  (1995),  GFAP  correlated  with  increased 
neurological disability (Table 3.6).
It is not known whether gliosis, i.e. proliferation and migration of glial  cells in 
damaged areas  of the  CNS,  observed  in  MS  has  overall  beneficial  or negative 
effects on disease progression. Therefore, while GFAP, as a marker, may have a 
solid biological rationale, its clinical relevance in MS is currently uncertain.
3.3.3.1  ELISA method to detect GFAP
Sandwich ELISA to detect GFAP has been described by Petzold et al  (2004). 
The  microtitre  plates  were  coated  with  mouse  monoclonal  IgGl  anti-GFAP 
antibodies  (Sternberg  Monoclonals,  Utherville,  MD):  lOOpl  of  the  capture 
antibody diluted in 1:1000 in 0.05M carbonate buffer, pH 9.5. The plate is washed
76with  barbitone  buffer  containing  0.1%  BSA  and  0.05%  Tween  20.  50pl  of 
barbitone buffer was  added in each well  followed by 50|d  standard,  control  or 
CSF sample in duplicates. The plates were incubated at room temperature for an 
hour  then  washed.  lOOpl  of HRP-labelled  rabbit  anti-bovine  GFAP  diluted 
1:1000 barbitone buffer were added to each well, incubated for an hour at room 
temperature and then washed.  The plate was incubated for 20 minutes at room 
temperature in the dark; the colour reaction was stopped with 50pl  1M HC1 and 
the absorbance read at 450 and 750nm on a Wallac Victor 2.  The normal  CSF 
reference range is 0.09ng/mL.
77Table 3.6  GFAP studies of MS
Year First
Author
Body fluid Cohort Observations
1986 Noppe CSF 535
neurological 
disease: MS, 
encephalitis, 
stroke, tumour 
compression
tGFAP dementia/syringomyelia
1995 Rosengren CSF 13 RRMS 
5 healthy 
control
TGFAP in MS 
GFAP correlate with 
neurological dysfunction.
2002 Petzold CSF
Brain
homogenate
51 MS 
(20RRMS, 
21SPMS, 10PPMS) 
51 OND 
PM brain tissue 
(12 MS, 8 control)
tGFAP in PM MS tissue
2003 Malmestrom CSF 66 MS (41 
RRMS, 25 SPMS) 
50 healthy 
control
TGFAP in SPMS
2004 Haghighi CSF 47CDMS 
47 healthy 
siblings
TGFAP in CDMS 
<->GFAP in siblings
f = increase; < -►  = no change/constant
783.3.4  Ferritin
About one third of iron in the brain is bound to ferritin, which has traditionally 
been thought of as the intracellular storage protein for iron.
Ferritin is a large spherical protein made up  of heavy and light chain subunits, 
each of 21  and  19kDa, respectively. Brain ferritin (of about 450kDa) contains a 
higher proportion of heavy to light chain subunits and a lower proportion of iron 
atoms per molecule than non brain ferritin. The heavy chain form of ferritin may 
allow  for  more  rapid  mobilization  of iron than  the  light  chain  form,  which  is 
associated with longer storage of iron.
Apart from the choroids plexus which stains strongly for iron, the other principle 
cells that stain for iron within the brain are oligodendrocytes.  Iron also stains in 
microglia, astrocytes, neuronal cell bodies, and possibly even axons and myelin 
sheaths (Koeppen, 2003). Iron uptake is maximal during rapid brain growth which 
coincides  with  the  peak  myelinogenesis.  Conversely  iron  deficiency  has  been 
associated  with  hypomyelination  at  development.  Iron  is  thus  vital  for 
myelination but its continuous requirement for myelin maintenance is less clear.
Ferritin  has  been  presented  as  a  general  marker  for  normal  and  activated 
microglia. The accumulation of iron and ferritin in microglia in diseased brain is 
not necessarily associated with an increase of total brain iron (e.g. total brain iron 
is  not  increased  in  Alzheimer’s  disease).  During  stresses  like  hypoxia, 
oligodendrocytes can increase their synthesis of ferritin,  to protect cells against 
oxidative damage, by sequestering iron which is toxic in a free or loosely bound
79state.  In normal adult human brain tissue,  ferritin binds predominantly to white 
matter and has the potential to deliver approximately 2000 times more iron than 
transferrin. Of note, iron levels in white matter are higher than in grey matter.
CSF  ferritin  has  been  shown  to  be  largely  non-glycosylated  (compared  with 
blood) and high  levels  have been associated with diverse  conditions  including: 
subarachnoid  haemorrhage,  intraparenchymal  cerebrovascular  events  including 
haemorrhage  and  infarction,  miscellaneous  CNS  infections  and  circulatory 
disorders associated with vasculitis (Keir et al.,  1993).
The normal distribution of ferritin binding sites is altered in and around plaques 
from periventricular white matter isolated from MS brains (Hulet et al.,  1999). 
Ferritin levels were significantly elevated in the CSF of chronic progressive active 
MS patients compared to normal individuals (Levine et al.,  1999). This could be a 
defense mechanism to protect against iron induced oxidative damage. There was 
no difference between normal individuals and RRMS patients (whether they were 
active or stable).
3.3.4.1  ELISA method to detect ferritin
Assay plates were coated overnight at 4°C with  1   in 200 dilution (55pL rabbit 
anti-human ferritin serum (Dako Ltd., high Wycombe; product number A133) to 
1  lml of 0.05M carbonate buffer, pH 9.5). First antibody was decanted and 200pL
0.05%  BSA  was  added  and  rinsed  with  solution  and  then  decanted  again.
80Blocking  solution  (1%  bovine  serum  albumin)  was  added  and  left  at  room 
temperature  for an hour to  saturate  all unoccupied protein binding sites.  Wells 
were replaced with 40pL sample diluent prepared with 2ml blocking solution and 
18ml Tween solution. Fifty microlitres of standard/CSF/brain homogenate sample 
was added. Plates were covered with cling film and incubated for 2 hours at room 
temperature,  and  then  decanted  and  washed.  Eleven  microlitres  of  detector 
antibody  peroxidase-conjugated  rabbit  anti-human  ferritin  (Dako  Ltd.,  High 
Wycombe;  product PI45)  was  added to  llmL of sample  diluent.  One hundred 
microlitres of this were added to each well at room temperature for an hour. Plates 
were washed and the colour was developed with o-phenylenediamine. The optical 
density was read in a Wallac ELISA plate reader at a measuring wavelength of 
492nm against a reference wavelength of 405nm. The mean normal CSF ferritin 
concentration is 5.6pg/L.
81Table 3.7  Ferritin studies of MS
Year First Author Body fluid 
(Human)
Cohort Observations
1989 Valberg Serum 49 MS
49 healthy control
|  ferritin
1999 LeVine CSF 44 chronic progressive 
MS
42 control
|  ferritin in 
chronic
progressive MS 
<-»ferritin in 
RRMS
2002 Petzold CSF 51 MS tFerritin in
Brain
homogenate
(20RRMS,
21 SPMS, 10PPMS)
51 other neurological 
disorders
PM brain tissue (12 MS, 8 
control)
SPMS and in all 
lesion stages in 
PM
f = increase; < -►  = no change/constant
3.3.5  Anti-myelin antibodies
There are many reports demonstrating low affinity antimyelin autoantibodies by 
ELISA  in  sera  and  CSF  of patients  with  MS,  though  their  role  either  in  the 
disease’s  pathogenesis  or  in  predicting  outcome  is  still  not  defined.  However, 
high affinity anti-MBP or MOG antibodies appear to be more difficult to detect in 
the serum or CSF of patients with MS while anti-MOG antibodies can be found in 
MS CNS plaque tissue [Genain et al.,  1999].
823.3.5.1  Anti-Myelin Basic Protein
MBP accounts for about 30% of central myelin protein. It is not however a CNS 
myelin specific protein as it is also expressed in the peripheral nervous system as 
well  as  cells  of the  immune  system  (Pribyl  et al.,  1996).  Anti-MBP  antibody 
response  is a relatively common  sequel  to any  CNS  injury1 1   (Frick and  Stickl, 
1980; Paterson et al.  1981; Newcombe et al.,  1985; Baig et al.,  1991; Solders et
al.,  1992;  Wang  et  al,  1992b;  Olsson  et  al.,  1993).  Anti-MBP  response  also
1  " ) appears to accumulate with time  .
3.3.5.2  Anti-Myelin Oligodendocyte Glycoprotein
MOG is a 218-amino acid glycoprotein and constitutes of 0.01-0.05% of the total 
membrane  protein  (Brunner  et  al.,  1989).  It  is  exclusively  expressed  in 
oligodendrocytes (Gardinier et al.,  1992) and is located on the outer lamellae of 
oligodendroglial membranes and myelin.
MOG  is  sequestered  from  the  immune  system  by  the  endothelial  blood-brain 
barrier  and  lack  any  direct  lymphoid  drainage  from  the  CNS  compartment. 
However  it  is  apparent  that  immune  sequestration  does  not  render  MOG 
uniformly  immunogenic  in  all  patients,  as  only  40-50%  of  MS  and  other
"  Healthy  subjects;  OND  -  Lyme  neuroborreliosis,  syphilis,  cerebrovascular 
diseases;  other inflammatory neurological disorders  -  ON,  subacute sclerosing 
panenchephalitis,  motor  neurone  disease,  hereditary  motor  and  sensory 
neuropathy; other non-neurological disorders - carcinoma, rheumatoid arthritis.
1 2  In contrast to anti-MOG-lg which does not differ with time and subsets of MS 
patients.
83inflammatory neurological disorders samples was anti-MOG-Ig antibody positive 
(Reindl etal,  1999).
Overall,  MOG  is  highly  immunogenic  and MOG  immunization  induces  severe 
relapsing  EAE  in  rodents  and  marmoset  (Stefferl  et  al,  2000).  The  immuno­
dominant target for this demyelinating autoantibody response is directed against 
the extracellular Ig domain of the protein (Adelmann et al.,  1995; Genain et al., 
1995).  Furthermore,  T  cells  proliferate  to  MOG  more  than  to  other  myelin 
antigens in patients with MS (Berger et al, 2003).
MOG  may  be  dependent  on  synergy  with  a  T-cell  mediated  inflammatory 
response in the CNS. Circulating pathogenic anti-MOG antibodies are unable to 
induce demyelination per se. Only when blood brain permeability is enhanced can 
antibody enter the  CNS,  bind to  the  myelin  surface  and  initiate  demyelination 
(Litzenburger etal  1998).
Recent  data  suggest  that  its  autoimmune  response  is  in  part  regulated  by 
polymorphisms  in  the  MOG  gene,  implicating  the  genetic  and  immunological 
stratification of patients with MS (Gomez-Lira et al 2002). Anti-MOG antibodies 
fix  complement  and  are  bound  to  disintegrating  myelin  in  acute  MS  lesions. 
Enhanced T- and B-cells responses to MOG have been reported in MS (Sun et al, 
1991;  Xiao et al,  1991; Kerlero de Rosbo et al,  1993;  Wallstrom et al,  1998) 
(Table  3.9).  Berger et al  (2003)  used the  first  102  N-terminal  amino  acids  of 
recombinant human MOG, expressed in Escherichia coli, as the antigen in their 
Western  blot  analyses  and  previous  ELIS  As  (Berger  et  al,  2003).  His  group
84found that the antibodies are present in the serum and CSF of a third of patients at 
the time of their first attack of MS (Berger et al, 2003).
The anti-MOG-Ig antibody response appears to be established early in the course 
of MS and does not differ significantly between the different patient subsets, i.e. 
CSF anti-MOG index is persistently higher in all stages of MS.  However,  it is 
unlikely that MOG is the only autoantigen expressed on the myelin surface that 
can be targeted by a pathogenic antoantibody response in MS.
3.4  Summary
In this chapter,  conventional MRI,  traditional  CSF  oligoclonal bands and some 
novel brain specific proteins have been reviewed.
Early pathological  changes  in MS  may contribute to later long term disability. 
Therefore  prevention  of  early  abnormality  may  be  the  best  way  to  prevent 
disability.  But  the  main  question  is  which  changes  in  early  MS  should  be 
targeted? For this reason, it would be desirable to study CIS patients with BSP, as 
BSP could provide further insight into pathological mechanisms in early disease.
Chapter 5 asks what insight can be learnt about pathological mechanisms in ON 
with BSP for neuronal loss (NfH) and myelination (ferritin). Are these BSPs more 
abnormal  in patients  with ON who  subsequently convert to  CDMS  or in those 
with non-MS-ON?
85Chapter 5 asks what is the key determinant of poor relapse recovery. Again, BSPs 
could provide valuable insights. Does higher levels of NfH predict poor outcome? 
Do steroids improve axonal loss?
There  is  also  a  need  to  correlate  histopathology  with  BSP  to  gain  further 
understanding  about  what  BSP  abnormality  means.  This  data  is  presented  in 
chapter 6.
Questions  also  remain  as to  whether serum  BSPs  could be  useful  as  surrogate 
markers.  Long-term disability develops over decades and the effect of therapies 
on  preventing  long-term  disability  cannot  be  assessed  with  clinical  endpoints. 
Therefore it is necessary to find surrogate markers which are:
1)  markers for pathology (e.g. axonal loss) that cause disability,
2)  that predicts long term disability, and
3)  are abnormal in early MS.
Two studies were done  in the present thesis, asking questions about surrogates. 
Chapter 7 asks whether S100B  increase over time in PPMS -  investigating any 
usefulness of serum S100B  as a surrogate marker.  Chapter 8  evaluates whether 
anti-myelin antibodies predict conversion of CIS to CDMS, in light of the recent 
positive findings by Berger and colleagues (2003).
86First Author Body fluid Subjects Results Comment
Lampasona
2004
Serum 87 MS patients 
12 encephalomyelitis 
47 healthy control
+ve anti-MOG IgM  in 40/87 MS patients and in control subjects. 
+ve anti-MOG IgG and IgM in all groups and subgroups.
Anti-MOG Ab are not disease specific
Mantegazza
2004
Paired
serum/CSF
262 MS patients; 175 RRMS, 
43 PPMS, 44 SPMS; 131 
OND, 307 healthy controls 
(sera only)
+ve serum anti-MOG Ab in 13.7% MS patients, 13.7% of OND patients , 6.2% of 
controls.
+ve CSF anti-MOG antibodies in 11.4% MS patients, 18.9% OND patients.
Anti-MOG Ab are not disease specific
Berger 2003 Serum 103 patients with CIS 
(positive findings on cerebral 
MRI, and oligoclonal bands 
in CSF).
9/39 seronegative Ab patients had a relapse within mean time 45.1+/-13.7 months. 
21/22 patients with Ab against both MOG and MBP had a relapse within 7.5+/-4.4 
months,
35/42 patients with anti-MOG Ab had a relapse within 14.6+/-9.6 months.
The adjusted hazard ratio for the development of CDMS was 76.5 (95% Cl, 20.6 to 
284.6) among the patients who were seropositive for both Abs.
+ve anti-MOG and anti-MBP Ab  had 
relapses more often and earlier than 
patients without these antibodies. 
Anti-MOG and anti-MBP together 
allows the prediction of early 
conversion to CDMS.
Markovic.
2003
CSF 44 MS patients 
51 controls 
11 with OIND 
40 with NIND.
+ve anti-MOG Ab in 30% MS patients was significantly | than NIND (8%, 
p=0.02), but not compared to OIND group (55%, p=0.228). +ve anti-MOG Ab was 
similar in patients with clinically active and stable MS (32% and 26%, 
respectively; p=0.921).
Anti-MOG Ab has potential role in the 
subset of patients with MS.
Kennel De 
March 2003
Serum 44 MS patients 
30 controls
t anti-MOG Ab levels in MS patients. Anti-MOG humoral immunity has a 
role in the pathophysiology of MS.
Tejada-Simon
2002
Serum 20 MS patients; 14 RRMS, 6 
chronic progressive MS 
10 healthy subjects
Anti-MOG Ab derived from MS patients displayed a skewed reactivity pattern, 
even though the occurrence and titres of serum anti-MOG Ab were only slightly | 
in MS patients.
Anti-MOG antibodies are present 
within demyelinating lesions of MS
Egg 2001 Serum 261 MS patients 72% had anti-MOG Ab, 59% were anti-MBP +ve.
Patients who actually suffered from a relapse were significantly more often anti- 
MOG and anti-MBP lgG3 +ve than those in remission.
t anti-MOG levels in MS patients and 
is associated with relapse.
Reindl 1999 Serum
CSF
130 MS patients, 32 patients 
with OIND, 30 patients with 
NIND, 10 patients with 
rheumatoid arthritis- sera only
+ve anti-MOG-Ig: 38% of MS patients 
53% in OIND 
3% in rare in NIND 
10% in rheumatoid arthritis.
Anti-MOG Ab are common in CNS 
inflammation. However, in OIND 
these antibody responses are transient, 
whereas they persist in MS.
Kami 1999 Paired
CSF/plasma
31 patients with MS 
31 OND, 28 healthy controls 
(sera only)
|CSF anti-MOG Ab in patients with MS and OND compared with controls, 
t plasma anti-MOG Ab in MS patients > OND and controls.
j anti-MOG Ab is not specific for MS 
because a similar appearance was also 
demonstrated in patients with OND.
Xiao 1991 Paired
CSF/plasma
30 MS patients, 30 with 
OND, 30 with headache
+ve anti-MOG Ab in CSF of 7 MS patients, 2 with OND, 1  with tension headache. 
No anti-MOG IgG antibodies were demonstrable in plasma
The significance of CSF anti-MOG Ab 
remains to be defined.
Table 3.8  Anti-MOG antibody studies in MS  +ve=positive  t=elevated
87PART 2
BRAIN SPECIFIC PROTEINS IN PATIENTS WITH 
DEMYELINATING DISEASES AND IN POST MOSTEM 
BRAINS WITH MULTIPLE SCLEROSIS
88Chapter 4
Cerebrospinal Fluid Levels of Brain Specific Proteins in Optic Neuritis
4.1  Introduction
The aim of this study is to evaluate the levels of CSF BSP in subjects with ON 
who are at high risk of progression to MS. It is important to study such patients, 
as early treatment in MS may be the most effective way at preventing long-term 
disability.  It  would  therefore  be  desirable  to  understand  the  pathological 
mechanism that occur early but which may be associated with later disability. The 
study was achieved in association with the group in the Division of Neurology 
and Department of Ophthalmology in Karolinska Institute, Huddinge University 
Hospital,  Stockholm.  With  the  above  hypothesis  in  mind,  CSF  from  the  ON 
cohort obtained from Stockholm was investigated forNfH, S100B and ferritin.
Acute  monosymptomatic  ON  can  be  the  first  presentation  of  MS.  It  is  an 
inflammatory demyelinating condition, and long-term follow-up indicates that up 
to 75% of subjects with ON will develop CDMS (Hickman et al., 2002; Francis et 
al., 1987; Rizzo et al., 1988; Brex et al., 2002). Between 50-70% of subjects with 
monosymptomatic ON have clinically silent MS-like lesions on brain MRI, and 
60-70% have the local synthesis of oligoclonal IgG bands typically seen in MS, 
(provided  sensitive  techniques  are  used)  (Soderstrom  et  al.,  1998).  Intrathecal 
immunoglobulin  synthesis  (e.g.  oligoclonal  IgG  bands),  in  monosymptomatic
89patients  is  also  strongly  predictive  for  the  future  development  of  CDMS 
(Soderstrom etal., 1998; Keir etal, 1993).
As mentioned previously, BSP are detectable in the CSF in a number of differing 
neuro-pathological  processes.  In  particular,  ferritin  a  marker  of  microglial 
activation (Keir et al,  1993),  S100B a marker of astrocytic activation (Green et 
al.,  1997) and two neurofilament heavy chain phosphoforms  (NfH SM I34 and 
NfH SM I35) putative markers  of axonal  degeneration (Petzold et al.,  2003).  The 
neurofilaments  differ  in  their  degree  of  phosphorylation;  NfH  SM I34  is  more 
extensively phosphorylated than NfH SM I35 (Petzold et al., 2003).
4.2  Aims
The  hypothesis  is  that  CSF  BSP  levels  in  subjects  with  ON  who  remain 
monosymptomatic (without eventual progression to MS), would differ from levels 
in subjects with ON destined to develop further episodes of CNS inflammation. 
To  test  this  hypothesis  the  levels  of ferritin,  a  microglial  activation  marker, 
S100B, a marker of astrocyte activation, and NfH S M 134 and NfH SM 135 in the CSF 
of ON patients were determined, comparing those at high risk of progression to 
MS (MRI positive and OCB positive) with those who are MRI and OCB negative.
Secondly, BSP levels were compared in those who developed CDMS on follow 
up with those who remained monosymptomatic.
90A third objective was to compare cross-sectional differences in levels of BSP in 
all subjects with ON, including those with MS, to those with other neurological 
diseases.
4.3  Methods
4.3.1  Subjects
Forty  one  subjects  who  had  acute  monosymptomatic  unilateral  ON  were 
consecutively recruited from the Stockholm Optic Neuritis Study. The outlines of 
this study and the protocol for clinical examinations, CSF and MRI investigations 
have been described in detail elsewhere (Soderstrom et al.,  1998). In all patients, 
blood tests,  lumbar puncture and MRI were performed within four weeks from 
onset of visual symptoms of ON.
Twenty one subjects had intrathecal IgG synthesis, i.e. oligoclonal IgG bands in 
CSF  which  were  absent  in  a  corresponding  serum  sample,  and  a  brain  MRI 
fulfilling the Paty criteria (Paty et al.,  1988) for being highly suggestive of MS 
thus representing “MS-type ON”. One subject had oligoclonal IgG bands in CSF 
but not in serum, but did not have a MRI performed. Nineteen subjects showed no 
signs of intrathecal immunoglobulin synthesis (absence of oligoclonal IgG bands 
and normal IgG-index) and had a normal brain MRI thus representing “non-MS- 
type ON”.
91Routine blood tests, a screen for collagen vascular disease and serologic tests for 
Lyme neuroborreliosis and neurosyphilis in CSF were normal or negative for all 
patients.
Seventeen  subjects  with  other neurological  diseases  (OND)  served as  controls. 
The clinical features of those with OND are summarized in Table 4.1.
4.3.2  Follow-up
None  of the  ON patients  received  oral  or  intravenous  corticosteroids  as  acute 
treatment or during the follow-up. Eighteen of the patients initiated treatment with 
intramuscular  interferon-beta-1  a  30  meg  once  weekly  (Avonex™)  during  the 
follow-up period.  The decision to  initiate this disease modifying treatment was 
based on clinical judgment and patient acceptance.
The patients  were  monitored  closely during the  first  six months  and  thereafter 
regularly every six months. They were instructed to contact the department if they 
experienced  any  ophthalmological  or  neurological  disturbances.  Eight  subjects 
with MS-type ON subsequently developed new neurological signs at median of 
18  (11-25) months and were diagnosed with CDMS  according to Poser criteria 
(Poser et al.,  1983).  All  of them  had been  started on  intramuscular interferon- 
beta-la 30 meg once weekly (Avonex™).
92The  Ethics  Committee  of  the  Karolinska  Institute  at  Huddinge  University 
Hospital, Stockholm, Sweden, approved the study protocol and informed consent 
was obtained from all patients.
4.3.3 CSF analysis
Total  protein,  ferritin,  S100B,  phosphorylated  and  extensively  phosphorylated 
neurofilament heavy chain (NfH SM I35 and NfH SM 134 respectively) were quantified 
in the CSF of all the subjects.
CSF samples were kept frozen at -40°C until the time of analysis.
4.3.4  Oligoclonal Bands, Total Protein, SIOOB and Ferritin
Oligoclonal bands in CSF and serum were determined using isoelectric focusing 
and  immunofixation using a standard method (Keir et al,  1990).  Total protein 
concentration was measured using the Lowry method.  S100B was quantified in 
CSF  by ELISA  as previously described by Green et al,  without  EDTA  in  the 
washing solution (Green et al.,  1997). Ferritin was determined in CSF by ELISA 
with the normal range being equal or less than 12ng/mL (Keir et al., 1993).
4.3.5  Neurofilament Heavy Chains (NfHSM I35 and NfHSM l3 4 )
The  two  neurofilament  heavy  chain  phosphoforms  were  detected  in  CSF  by 
sandwich ELISA assay as described by Petzold et al.  (2003).
934.3.6  Statistical analysis
All CSF tests were performed with researchers blinded to the clinical diagnosis 
and MRI results. Statistical analyses: median, interquartile range and significance 
of group  differences  (Mann-Whitney  U  tests)  were  evaluated  using  the  SPSS 
software package (version  11.0 for Windows).  Probability values less than 0.05 
were considered significant. Three subgroup analyses were undertaken;
1.  Subjects  who  developed  CDMS  (ON(CDMS))  versus  those  that  are 
negative for both CSF/serum OCB and have normal MRI (non-MS-type ON).
2.  Subjects with MS-type ON and non-MS-type ON;
3.  All  subjects  with  optic  neuritis  (ON  total)  and  those  with  other 
neurological diseases (OND);
Relationships between parameters were assessed using Spearman rank correlation 
coefficient (r).
The degree of phosphorylation of the neurofilament phosphoforms was expressed 
as a ratio of NfHSM I34 to NfHSM I35. A ratio of less than  1   is thought to indicate a 
relative  decrease  in NfH  phosphorylation  a putative  marker of damaged axons 
(see Figure 4.1).
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Figure 4.1  Schematic diagram of the degree of phosphorylation of healthy axons 
vs.  damaged  axons  and  the  significance  of  the  ratio  for  neurofilament 
phosphoforms.
4.4  Results
The  demographics  for  all  subjects  and  for  the  six  separate  group  types  are 
described  in  Table  4.2.  There  were  no  significant  differences  in  any  of the 
subgroups in relation to sex and age. CSF oligoclonal IgG bands were present in 
61% of all subjects with ON (total) and  100% in those with ON (CDMS) and by 
definition in 100% of subjects with MS-type-ON. None of the subjects with non- 
MS-type ON and OND was positive for CSF oligoclonal IgG bands.
4.4.1  ON (total) vs. OND (Table 4.3)
NfHSM i34  was  significantly elevated  in  subjects  with ON  compared  to  controls 
(Figure 4.2). No such difference was found for NfHSM I35 in ON (total) vs. OND. 
The NfHSM I34:SM I35 ratio was higher in all  subjects with ON when compared to 
OND (Figure 4.3). S100B levels were similar in all subjects studied. Lower levels 
of CSF ferritin were observed in all subjects with ON (total) compared to those 
with  OND.  The  CSF  total  protein  was  higher  in  all  subjects  with  ON  (total)
95compared  to  control.  CSF  total  protein  correlated  with  S100B  in  ON(total) 
(r=0.41, p=0.01) and OND subjects (r=0.60, p=0.01) and CSF ferritin with CSF 
total protein in all subjects with ON(total) (r=0.36, p=0.03).
4.4.2  ON (CDMS) vs. Non-MS-type ON
There were no significant differences in the levels of CSF brain specific proteins 
when ON subjects that subsequently went on to develop CDMS were compared 
with ON subjects with normal MRI and negative CSF/serum OB.
4.4.3  MS-type ON vs. Non-MS-type ON (Table 4.3)
When comparing MS-type ON with non-MS-type ON, the total protein in CSF 
was  higher  in  the  former  subgroup  but  the  difference  was  not  statistically 
significant (p=0.08). CSF NfHSM I34 and NfHSM I35 levels as well as the degree of 
phosphorylation  did  not  differ  between  MS-type  ON  and  non-MS-type  ON. 
Ferritin and S100B levels were similar in both groups. There were no correlations 
between age, ferritin, S100B, neurofilament heavy chain phosphoforms and total 
protein in MS-type ON and non-MS type ON.
4.S  Discussion
Neurofilament heavy chain levels and the NfHSM I34: SM I35 ratio,  thought to be a 
relative  index  of NfH  phosphorylation  status,  were  increased  in  the  CSF  of 
subjects  with  optic  neuritis  whereas  levels  of  S100B  did  not  differ  between
96subjects  with  optic  neuritis  and  neurological  controls.  CSF  ferritin  was 
significantly  lower  in  these  two  groups but the  levels  were  within  the  normal 
limits.
Neurofilament heavy chain is thought to be a marker of axonal pathology and its 
release  into  the  CSF  in  optic  neuritis  may  indicate  that  acute  axonal  damage 
and/or loss  is  occurring in this condition.  There  are  different phosphoforms  of 
neurofilament  heavy  chain (Goldstein  et  al  1983),  and  this  study  shows  that 
extensively phosphorylated neurofilament heavy chains are released into the CSF 
in optic neuritis.  Extensively phosphorylated isoforms of NF are found in large 
healthy axons compared to the less phosphorylated isoforms that are indicative of 
axonal  pathology (Trapp  et al,  1988).  Therefore  raised  levels  of extensively 
phosphorylated isoforms indicate damage and release of NfH from healthy axons. 
This is what one would expect in subjects presenting with their initial attack. In 
comparison  in  subjects with more established MS  in which significant damage 
has already occurred to the CNS. Petzold et al  (2002) have shown that that the 
ratio of extensively phosphorylated to phosphorylated NfH (NfHSM I34:SM I35) to be 
reduced in patients with progressive and advancing MS compared to patients with 
non-advancing relapsing disease.  They have also observed high  levels  of CSF 
NfHSM I35 in CSF of patients with subarachnoid haemorrhage, amyotrophic lateral 
sclerosis, space occupying lesions and disc prolapses (Petzold et al, 2003).
97Those with ON who are at high risk of progression to MS (subjects with white 
matter lesions on MRI  and local synthesis of oligoclonal bands) had CSF BSP 
levels  similar to  those  at  low risk.  Furthermore,  a retrospective  comparison of 
subjects who subsequently went on to develop  CDMS  with those who did not, 
revealed no difference in baseline CSF BSP levels. It is of relevance that 86% of 
the subjects with MS-type ON which include all of the subjects who subsequently 
developed CDMS were on intramuscular interferon-beta-la 30 meg once weekly 
(Avonex™).  This  disease  modifying  therapy  may  have  delayed  conversion  to 
CDMS  and/or  slowed  down  axonal  damage  or  atrophy,  hence  a  source  of 
confounding error in the lack of difference seen.
Another explanation for the lack of difference is that although levels of lumbar 
CSF BSP may be indicative of recent pathology they may not provide information 
about  ongoing  inflammation.  In  this  sense,  it  should  be  noted  that  CSF 
examination was performed within a month of symptom onset.  Furthermore, the 
pathology of optic neuritis, irrespective of the risk for further attacks is likely to 
be similar, and involve axonal loss. Therefore levels of BSP would be similar in 
all  cases  of  ON.  In  one  study,  no  differences  were  noted  for  a  number  of 
cytokines measured by in situ hybridization between MS-type ON vs. non MS- 
type ON, concluding that the inflammatory markers in blood and CSF was more 
related to the inflammation per se (in the optic nerve) than to MS (Kivisakk et al., 
1997).
98Axonal damage has been observed in patients with ON (ophthalmic examination 
reveals subtle atrophy of the retinal nerve fibre layer (Frisen et al.,  1974)) and in 
an experimental model of optic neuritis where the presence of axonal cytoskeletal 
changes  has  been  detected (Zhu  et al.,  1999).  Acute  inflammation  may  be  an 
important cause of axonal loss in both MS and EAE (Ferguson et al., 1997; Trapp 
et al.,  1988) and therefore it is likely that these mechanisms also exist in ON. In 
MRI studies, low concentration of the metabolite N-acetyl aspartate is thought to 
be a marker of axonal loss or damage and has been found occurring focally at the 
earliest phase  of the  disease.  This  reduction however was  not  seen  in NAWM 
demonstrating that widespread axonal changes are not yet detectable in the early 
clinical  stage  (Brex  et al.,  1999;  Hickman et al.,  2001).  This  may explain  the 
significant difference in neurofilament levels detected between subjects with optic 
neuritis and controls, and at the same time, the lack of detectable difference seen 
between  those  with  acute  monosymptomatic  ON  and  those  that  progressed  to 
develop CDMS.
The  lack  of difference  in  S100B  levels  between  subjects  with  ON  and  other 
neurological controls suggests that the astroglial activation, which occurs in the 
optic nerve as a result of inflammation, cannot be detected in the lumbar CSF.
CSF ferritin was not raised in subjects with ON. This finding is  similar to that 
reported in RRMS (Petzold et al,  2002). In comparison CSF ferritin is raised in 
SPMS. A number of mechanisms have been proposed for the alterations observed
99in  CSF  ferritin  levels,  and  these  include  an  elevation  seen  in  association  with 
microglial  activation.  Disorders  associated  with  intracranial  haemorrhage  and 
necrosis  also results  in an  increase  in  CSF  ferritin (Keir et al,  1993).  Finally, 
oligodendrocytes require iron to synthesize myelin [Hulet et al.,  1999] and ferritin 
binding  is  decreased  in  MS  lesions  (suggesting  that  oligodendrocytes  bind 
myelin) (Connor et al,  1996).  It is plausible therefore that reduced CSF ferritin 
may occur with remyelination.
The observation that ferritin levels were depressed in this cohort of ON subjects is 
intriguing. One explanation is that the neurological controls had mildly elevated 
levels.  An alternative explanation is that remyelination could be accounting for 
the ferritin reduction.  A phase  of active remyelination is likely to occur in the 
weeks following optic neuritis and this change would therefore coincide with the 
timing of the CSF examination in this study. These observations will need to be 
confirmed.
This  study  has  shown  that  following  ON,  hyperphosphorylated  neurofilament 
heavy  chain  is  increased  while  ferritin  may  be  reduced  in  the  CSF,  a  month 
following symptom onset. This suggests, as expected, that acute axonal damage, 
of “healthy axons”, is a feature of optic neuritis and that remyelination may also 
be occurring at this stage. BSP measured in CSF may be useful markers of acute 
pathological  change.  Whether  changes  in  CSF  levels  of BSP  are  capable  of 
predicting outcome in demyelinating disease requires further study.
100Table 4.1 Characteristics of subjects with other neurological disease
Subjects Age (yrs) Sex Diagnosis
1 73 F Normal pressure hydrocephalus
2 29 M Depression
3 32 F Tension headache
4 36 F Tension headache
5 65 F Normal pressure hydrocephalus
6 54 F Tension headache
7 52 M Normal pressure hydrocephalus
8 23 F Tension headache
9 69 F Frontotemporal atrophy
10 27 F Tension headache
11 23 F Benign intracranial hypertension
12 51 F Blepharospasm
13 68 F Parkinson’s Disease
14 43 M Parkinson’s Disease
15 23 F Atrophy of cerebellum
16 67 F Normal pressure hydrocephalus
17 21 F Hereditary ataxia
Yrs,years; M,male; F,female.
101Table 4.2 Clinical characteristics of subjects
OND ON(total) ON(CDMS) MS-type Non-MS-
(n=17) (n=41) (n=8) ON type ON
(n=2l') (n=19)
Male:Female 3:14 13:28 2:6 4:17 8:11
Age (yrs) 36.0 36.0 43.0 36.0 38.0
(32.0-44.0) (31.0-43.5) (25.0-6.0) (29.5-42.0) (32.0-44.0)
MS-type ON,  subjects  with positive MRI and CSF oligoclonal bands; Non-MS- 
type  ON,  subjects  with  normal  MRI  and  negative  CSF  oligoclonal  bands; 
ON  (total),all  subjects  with  optic  neuritis;  ON  (CDMS),  optic  neuritis  with 
clinically definite MS; OND, other neurological disorders; n, number of subjects; 
yrs,years.
Age expressed as median (interquartile range).
One subject had oligoclonal IgG bands in CSF but not in serum, but did not have 
a MRI done.
102Table 4.3  CSF characteristics expressed as median (interquartile range)
BSP OND ON(total) ON(CDMS) MS-type ON Non-MS-
markers (n=17) (n=41) (n=8) (n=21*) type ON 
(n=19)
OB; Not done 22:19 8:0 21:0 0:19
PosiNeg 54 100 100 0
% n=41 n=8 n=21 n=19
Total 0.41a 0.508 0.55 0.58 0.47
protein (0.36- (0.39-0.60) (0.43-0.55) (0.44-0.61) (0.35-0.56)
(g/L) 0.48)
n=16
n=39 n=8 n=21 n=17
Ferritin 7.0 6.0 6.0 6.0 6.0
(ng/mL) (6.0-10.0) (4.0-6.0) (4.0-6.0) (4.0-6.0) (4.0-6.5)
n=l 1
3
I
I
U
J
n=8 n=19 n=17
S100B 0.57 0.56 0.55 0.54 0.57
(ng/mL) (0.41- (0.41-0.72) (0.43-0.60) (0.40-0.76) (0.41-0.71)
0.83)
n=17
n=41 n=8 n=21 n=19
NfHSM I34 0.03b 0.21b 0.06 0.14 0.25
(ng/mL) (0.00- (0.00-0.87) (0.00-0.50) (0.00-0.93) (0.00-0.94)
0.13)
n=14
n=37 n=8 n=18 n=18
NfHSM I3S 0.17 0.14 0.15 0.14 0.15
(ng/mL) (0.14- (0.11-0.18) (0.09-0.18) (0.12-0.17) (0.11-0.22)
0.23)
n=
17
n=41 n=8 n=21 n=19
NfHSM I34: 0.20° 1.90c 0.70 1.08 1.90
SM I35 (0.00- (0.00-6.37) (0.07-4.20) (0.00-6.72) (0.00-6.03)
0.75)
n=14
n=36 n=7 n=17 n=18
ON(total),all subjects with optic neuritis;  ON(CDMS), optic neuritis with clinically definite MS;
MS-type-ON,  subjects positive for MRI and oligoclonal bands;  non-MS-type-ON,  subjects  with 
normal  MRI  and  negative for  oligoclonal  bands;  pos,positive for  CSF  oligoclonal  bands; 
neg, negative  for CSF oligoclonal bands.
103(continuation Table 4.3)
P values calculated by Mann-Whitney U Test.
^Significant P value is taken at  0.05 level.
*One subject had oligoclonal IgG bands in CSF but not in serum, but did not have 
a MRI done.
Figure  4.2  Box-and-whiskers  plot  of  levels  of extensively  phosphorylated 
neurofilaments  in  subjects  with  optic  neuritis  (n=41)  and  those  with  other 
neurological disorders (n= 17) was significantly different (***P<0.05).
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Figure 4.3  Box-and-whiskers  plot  levels  of the  ratio  NfHSM B4:NfHSM I35  in 
subjects  with  optic  neuritis  (n=36)  and  that  with  other  neurological  disorders 
(n=14) was significantly different (***P<0.05).
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105Chapter 5
Cerebrospinal fluid levels of neurofllament heavy chain in acute optic 
neuritis and multiple sclerosis patients treated with oral high-dose
methylprednisolone
5.1  Introduction
Following from the previous chapter, it is important to confirm the findings and to 
determine whether CSF neurofilament heavy chain levels were associated with, 
(1) clinical outcome, (ii) with clinical response to treatment, and (iii) measures of 
disease activity in subjects with ON and MS.
This study was done in collaboration with the Denmark group in the Department 
of Neurology, University of Copenhagen, Glostrup, Denmark. The objective was 
to look at CSF neurofilament heavy chain levels in subjects who participated in 
two randomized, placebo controlled clinical trials that supported the use of high- 
dose  oral  methylprednisolone  therapy  for  ON  and  MS  attacks  respectively.  In 
addition levels of neurofilaments were compared with MBP because the latter has 
been found to be associated with clinical disability and has been suggested to be a 
potential surrogate marker of demyelination.
As  mentioned  previously,  glucocorticoid  treatment  reduces  inflammation  and 
accelerates  recovery  in  some  diseases.  The  efficacy  of  oral  high-dose 
methylprednisolone in attacks of optic neuritis (ON) and multiple sclerosis (MS)
106however  has  been  controversial.  Furthermore,  acute  inflammation  may  be  an 
important cause of axonal  loss and acute  axonal  damage  has been  observed  in 
subjects with ON and MS (Trapp  et al.  1988;  Lycke  et al.  1998;  Semra et al. 
2002).
As  mentioned  in  detail  in  chapter  3,  neurofilament  heavy  chain  is  a  highly 
phosporylated axonal protein found in all neuronal processes.  It controls axonal 
caliber by forming cross bridges  and by interacting with microtubules,  thereby 
preserving the morphological  integrity of axons and the conduction velocity of 
nerve impulses (Hoffman et al.,  1987). Its release into CSF in ON and MS may 
indicate that acute axonal loss is occurring in these conditions. High concentration 
of MBP has been found to be associated with clinical disability in patients with 
MS  and  ON (Thompson  et al.,  1985;  Barkhof et  al.,  1992a;  Sellebjerg  et al., 
1998b),  suggesting  its  potential  role  as  a  surrogate  marker  in  demyelinating 
disease.
5.2  Aims
This  study  looks  at  CSF  neurofilament  heavy  chain  levels  in  a  subgroup  of 
subjects  who  participated  in  two  randomized,  placebo-controlled  trials  that 
supported the use of oral high dose methylprednisolone in acute ON and attacks 
of MS (Sellebjerg et al.  1998a;  1999). The objective of this study is to determine 
whether  CSF  neurofilament  heavy  chain  levels  were  associated  with  clinical 
response to treatment and measures of disease activity including MBP.
1075.3  Methods
5.3.1  Patients and examination
Fifty  subjects  who  gave  informed  consent  to  participate  in  two  double  blind, 
randomised, placebo-controlled clinical trials were included in a repeated lumbar 
puncture  study (Sellebjerg  et  al,  1998a;  1999;  2000).  Eighteen  patients  were 
included in the ON trial (Sellebjerg et al,  1999) and 32 subjects were included in 
the MS attack trial (Sellebjerg et al,  1998a). Eight subjects with ON were treated 
with  oral  methylprednisolone  and  15  subjects  with  MS  attacks  also  received 
treatment  with  oral  methylprednisolone:  500mg  once  daily  for  5  days,  then 
weaned daily according to the following regime: 400mg, 300mg, 200mg,  lOOmg, 
64mg,  48mg,  32mg  16mg,  8mg  and  8  mg  once  daily,  i.e.,  a  total  treatment 
duration of 15 days. Twenty-seven subjects had oral placebo.
Figure 5.1  Number of subjects who received treatment
51  recruits
ON trial group  MS attack trial group 
(n=18)  (n=32)
Placebo  Steroids
(n=10)  (n=8)
Placebo  Steroids
(n=17)  (n=15)
108Subjects  in  the  ON  trial  received  scores  on  the  visual  function  system  of the 
Kurtzke EDSS (Kurtzke, 1983) and those in the MS attack trial received scores on 
the Kurtzke EDSS. Their clinical disability was assessed pre-treatment, and at  1, 
3,  8  and  52  weeks  post-treatment.  Lumbar  puncture  was  performed  prior  to 
treatment and a week after completing treatment.
5.3.2  MRI
MRI  of  the  brain  was  performed  a  median  of  one  day  prior  to  treatment 
(interquartile range 0-2 days) (Sellebjerg et al, 2003). Quantitative analysis of the 
enhancing  lesion  volume  (ELV)  was  measured,  and  T2-weighted  MRI  was 
classified  as normal  or being highly suggestive  of MS (Sellebjerg et al.,  2003; 
Paty et al.,  1988).
The regional scientific ethics committee approved the study.
5.3.3  CSF tests
CSF samples were kept frozen at -80°C until the time of analysis. All CSF tests 
were  performed  with  researchers  blinded  to  the  clinical  diagnosis  and  MRI 
results.  Total  protein  concentration  was  measured  using  the  Lowry  method. 
ELISA as previously described by Petzold et al. (2003) was used to quantify two 
subtypes  of  CSF  neurofilament  heavy  chains  levels.  CSF  NfHSM I35  is 
phosphorylated and NfHSM I34 is extensively phosphorylated neurofilament heavy 
chain  (Petzold  et  al.,  2003).  A  ratio  of NfHSM 134  to  NfHSM I35  was  also  used..
109Sellebjerg and colleagues had determined the CSF MBP levels in their laboratory 
in Denmark using a previously described method (Sellebjerg et al  1998b).
5.3.4  Statistical analyses
The  statistical  analysis  was  performed  in  conjuction  with  Dr  Daniel  Altmann 
(Medical  Statistics  Unit,  London  School  of  Hygiene  &  Tropical  Medicine, 
London). Ordered logistic regression with proportional odds assumption (Greene 
2000) was carried out in the MS and ON attack trial groups separately to examine 
associations between change in EDSS as an outcome and a neurofilament level 
predictor  variable;  EDSS  change  was  recoded  before  analysis  by  collapsing 
categories with 5 or less patients: for change 8 week - baseline these were [-3 to- 
1.5], [-1, -0.5], [0], [0.5 to 3], for 52 week -  baseline [-3.5 to -1.5], [-1, -0.5], [0 to 
5], and for 52 -8  week [-4 to -1],  [-0.5],  [0],  [0.5  to 2].  In the ON attack trial 
group the 8 week -  baseline categories were [-5, -4], [-3 to -1]; and the 52 week - 
baseline and 52-8 week categories were [-5, -4], [-3, -2], [-1, 0] and [-1, 0], [1] 
respectively.  The neurofilament predictors examined for CSF NfH and CSF NfH 
were  3  week  level,  and  the  change  in  level  3  week-baseline.  Potential 
confounding  by  age,  gender,  MS  duration,  symptom  duration  and  steroid 
treatment  was  examined  by  introducing  these  terms  as  covariates  in  the 
regression.  There was  no  evidence  in any of the models that the proportional 
odds assumption was not satisfied.
110The  two  trial  groups  were  combined  in  an  analysis  of a  dichotomised  EDSS 
change variable:  patients were classified according to whether they were  in the 
more  or less  deteriorating  (approximate) half of their respective  group.  EDSS 
changes 3 week -  baseline, 8 week -  baseline, 52 week -  baseline and 52 week - 
8 week were dichotomised.  The thresholds used for 3 week - baseline were EDSS 
change  < -0.5  in the MS  group and <-3  in the ON attack group;  for 8  week -  
baseline  the  respective  thresholds  were  <-1  and  <-4;  for  52  week  -   baseline 
respectively < -0.5 and < -3; and for 52 week -  8 week respective < -0.5 and < 0. 
The binary variables were  analysed by logistic regression on the neurofilament 
predictors, with covariates as above for examination of potential confounding.
The neurofilament variables were somewhat skewed, and the difference in these 
variables  between  treated  and  untreated  patients  (both  trial  groups  combined) 
were assessed using the Wilcoxon rank sum test.  Spearman rank correlation was 
used  to  examine  associations  between  these  variables  and  baseline  enhanced 
lesion volume.  Association between these variables and the three categories of 
T2-weighted MRI abnormality were examined by a non-parametric test for trend 
(Cuzick, 2001).  Spearman rank correlation was also used to examine associations 
between neurofilaments and MBP. Statistical analysis was performed using Stata 
7.0 (Stata Corporation) and SPSS 11.5.
Ill5.4  Results
5.4.1  CSF neurofilament heavy chain levels and clinical disability
5.4.1.1  MS attack trial zroup
The result of the ordered logistic regression to examine associations between CSF 
neurofilament  levels  and  change  in  clinical  outcome  are  shown  in  Table  5.1. 
There was evidence that absolute level of CSF NfHSM I35 predicted greater 0 to 8 
week  EDSS  deterioration  (odds  ratio  of being  in  worse  adjacent  category  of 
deterioration per unit increase in CSF NfHS M 135 was 4.24, 95% confidence interval
1.04  to  17.30;  p=0.044).  In  addition,  there  was  evidence  that  greater  clinical 
deterioration from 0 to 52 weeks was predicted by greater increase compared to 
baseline in 3 week CSF NfHSM I34 (odds ratio  1.76, 95% confidence interval  1.04 
to 2.98; p=0.035); and similar evidence for an association of this predictor with 
late EDSS deterioration 8 to 52 weeks (odds ratio 2.24, 95% confidence interval 
1.08, 4.64; p=0.030).  No evidence of any association was seen between the ratio 
of  NfHSM I34  to  NfHSM I35  and  clinical  disability.  There  was  no  evidence  of 
confounding by age, gender, MS duration, symptom duration or treatment.
5.4.1.2 ON attack trial group
In the ON trial group, there was no evidence of any association between the CSF 
neurofilament heavy chain levels and changes in EDSS.
1125.4.2 Effect of  treatment on clinical outcome
When both MS and ON trial groups were combined, there is some evidence that 
patients treated with steroids had less EDSS deterioration between baseline and 
week  3  (odds  ratio that  treated patients were  in the  more  deteriorating half of 
group was 0.30, 95% confidence interval 0.09 to 0.97; p=0.045).  However, there 
was no evidence of a treatment difference in the more long-term EDSS changes.
5.4.3  Effect of treatment on CSF neurofilament levels
Steroid treatment had no effect on the levels of CSF neurofilament heavy chains 
in the combined ON and MS group.
5.4.4 CSF neurofilament heavy chain levels and MRI measures (Table5.2)
Baseline CSF NfHSM I34 and NfHSM I35 were both significantly positively correlated 
with baseline ELV. The level of CSF NfHSM I35 at week 3 was also significantly 
positively  correlated  with  baseline  ELV,  whereas  there  was  only  a  borderline 
significant and reduced positive correlation between CSF NfHSM I34 measured at 
week  3  and  baseline  ELV.  There  was  also  borderline  evidence  of a  positive 
correlation between ELV and the CSF NfHSM I34 :NfHSM I35 ratio at baseline  and at 
week 3.
T2-weighted  MRI  abnormality  was  associated  with  higher  values  of  CSF 
NfHSM I35 at baseline and week 3 (p=0.005 and p=0.002 respectively), but not with 
the week 3 -  baseline change.  There was no evidence of association with CSF
113NfHSM I34 or the ratio NfHSM I34 :NfHSM I35 at either time point, nor with changes in 
these.
5.4.5  CSF neurofilament heavy chain levels and MBP
Figures 5.2 and 5.3 illustrate that CSF NfHSM I35 at baseline and week 3 were both 
statistically  significantly  positively  correlated  with  MBP  measured  at  baseline 
(r=0.56  p=0.006  and r=0.77  p<0.001)  and week 3  (r=0.63  p<0.001  and r=0.68 
p<0.001). CSF NfHSM 134 at week 3 correlated with the concentration of MBP at 
week 3 (r=0.58 p=0.004). It is known that methylprednisolone treatment results in 
a  marked  decrease  in  the  CSF  concentration  of MBP  [Barkhof  et  al.  1992; 
Sellebjerg  et  al.  2003].  Nonetheless  additional  analysis  in  the  steroid  treated 
group did not observe any correlation between the degree of MBP decrease and 
the amount of increase in levels of CSF neurofilament heavy chain.
5.5  Discussion
This  study  suggests  that  complex  changes  in  CSF  neurofilament phosphoform 
levels seen after the initial attack relate to clinical outcome in the subsequent two 
month to one year period in a cohort of subjects with clinically definite MS. As a 
consequence one is able to evaluate the health of the axons prior to damage, the 
extent  of the  damage,  and the  potential  for recovery or non-recovery over the 
subsequent months.
In the MS attack trial group, high levels of CSF neurofilaments are predictive of 
poorer clinical outcome and of continuing deterioration between 8 weeks and one
114year post-relapse. These new findings suggest that the degree of axonal damage 
from a relapse can determine functional impairment in the longer term. Although 
there was no statistical evidence of an association between clinical outcome and 
CSF  neurofilament  levels  when  the  ON  trial  group  was  taken  into  account 
separately, one must bear in mind that the ON sample size is small and that the 
patients with ON have no spinal cord disease. CSF BSP levels are more likely to 
be representative of what is occurring locally, i.e. in the spinal cord rather than in 
the optic nerve that is distal to the CSF outflow pathways of the IVth ventricle. Of 
note, when both groups were combined, we observe a similar pattern to that seen 
in the MS attack trial group alone.
The present study also shows that CSF neurofilament heavy chain levels correlate 
with  MBP,  gadolinium  enhancing  lesion  volume  and  T2-weighted  MRI 
abnormalities in subjects with ON and MS. High concentrations of the structural 
myelin protein, MBP in CSF is implicated in ongoing inflammation and has been 
found  to  be  associated  with  clinical  disability  in  patients  with  demyelinating 
disease (Thompson et al,  1985;  Barkhof et al.,  1992a;  Sellebjerg et al.,  2003), 
and steroid treatment results in suppression of gadolinium-enhancement and the a 
decrease in the concentration of MBP in CSF (Thompson et al.,  1985; Barkhof et 
al.,  1992a; Sellebjerg et al.,  2003). However, current results show no change in 
clinical  EDSS  outcome  with  steroid  treatment  at  one  year  which  raises  the 
question of how reliable EDSS is as a clinical measure.
115An  important  question  is  what  effects  anti-inflammatory  therapy  such  as 
methylprednisolone  has  on  axonal  markers  found  in  the  CSF?  The  treatment 
effect observed in the patient subgroups included in the present study confirm the 
earlier results which showed that after treatment with oral methylprednisolone in 
both ON and MS attack trial groups (Sellebjerg et al.,  1998a, 1999), the chance of 
worse clinical outcome is less, with a 70% reduction in odds estimated from our 
analysis, suggesting that steroids hastens recovery.
Axonal damage appears to be more marked in the most acute of lesions and so 
strategies that reduce inflammation would be expected to be neuroprotective. We 
have found that steroid treatment has no effect on the levels of CSF neurofilament 
heavy chain levels therefore the observed short term recovery post-steroid in both 
ON and MS group is independent of the release of neurofilaments.
Many studies have confirmed that axonal damage is found in MS plaques (Trapp 
et  al.,  1988;  Komek  and  Lassmann  1999;  Ferguson  et  al,  1997).  MRI  and 
spectroscopic  methods provide accurate means of assessing axon loss and have 
been shown to correlate with disability in MS (Matthews et al.,  1998; Grimaud et 
al.,  1999;  Paolillo et al.,  2000;  Pelletier et al.,  2001;  Fischer et al.,  2000). The 
findings  in  this  study  support  the  latter view  as  well  as  suggesting  that  acute 
inflammation  in  these  demyelinating  diseases  results  in  axonal  pathology. 
Furthermore, my results are in agreement with the notion that axonal degeneration 
may continue for some time after the resolution of inflammation.
116The relationship between the two different subtypes of neurofilament heavy chain 
is not understood. NfHSM I34 is more phosphorylated than NfHSM I35 and the latter is 
thought  to  be  indicative  of axons  subjected  to  chronic  injury.  Thus  a  ratio  of 
NfHSM i34 to NfHSM I35 is thought to represent a putative index of ‘axonal health’. 
This  hypothesis  however  was  not  confirmed  in  this  study.  Nonetheless, 
neurofilament deficient axons have the ability to regrow and remyelinate albeit at 
a slower rate (reviewed by Medana and Esiri, 2003).  Anti-inflammatory therapy 
has minimal effect on relapse response. Perhaps, therapeutic intervention should 
consider  targeting  axonal  recovery  that  seems  to  be  associated  with  future 
disability.
In conclusion the results of the present study provide evidence that the severity of 
axonal  damage  determines  clinical  outcome  and confirms previous  reports that 
acute inflammation in MS results in axonal pathology.
117Table 5.1  Results of ordered logistic regression in multiple sclerosis trial group 
examining association between EDSS change and neurofilament levels.
Variable P value*
EDSS change CSF NfHSMm 0.504
week 8 minus baseline at week 3
Change in CSF NfHSM IJ4 
at week 3 minus baseline
0.968
CSF NfHsM u:> 
at week 3
0.044
Change in CSF NfHSM U 5 
at week 3 minus baseline
0.503
EDSS change CSF NfHSMm 0.080
week 52 minus baseline at week 3
Change in CSF NfHS M 134 
at week 3 minus baseline
0.035
CSF NfHS M 135 
at week 3
0.566
Change in CSF NfHSM l35 
at week 3 minus baseline
0.243
EDSS change CSF NfHS M 134 0.080
week 52 minus week 8 at week 3
Change in CSF NfHSM l34 
at week 3 minus baseline
0.030
CSF NfHSM l35 
at week 3
0.336
Change in CSF NfHSM U 5 
at week 3 minus baseline
0.254
NfH  ,  phosphorylated  neurofilament;  NfH  ,  extensively  phosphorylated 
neurofilament;  NfHS M I34  S M I35,  ratio  of  extensively  phosphorylated  neurofilament  to 
phosphorylated neurofilament; week 3, one week post-treatment.
aThe P-value tests the null hypothesis that odds of being in a higher category of EDSS 
change do not vary with values of the neurofilament predictor.  P-values rejecting null 
hypothesis give evidence that higher predictor levels are associated with greater clinical 
deterioration.
118Table  5.2  Spearman rank correlation coefficients were used to examine
associations  between  CSF  neurofilament  heavy  chain  levels  and  baseline  T1 
weighted MRI gadolinium area (enhancing lesion volume).
Variable Spearman
correlation
coefficient
P-value
CSF NfHSM I34 at baseline 0.50 0.005a
CSF NfHSM I34 at week 3 0.33 0.06
CSF NfHSM I35 at baseline 0.53
s
>
O
©
V
CSF NfHSM I35at week 3 0.65 <0.0 lc
NfHSM I34:NfHSM I35at baseline 0.39 0.07
NfHSM I34:NfHSM I35at week 3 0.42 0.05d
NfhfM I34 SM B5t ratio of extensively phosphorylated neurofdament to phosphorylated neurofdament
P-values calculated by Spearman rank correlation. 
a,b ,c,d  sign|f|ca„t p value is taken at  0.05 level.
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Figure 5.2  The association between neurofilament and myelin basic protein at
baseline in the placebo group.
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Figure 5.3  The association between neurofilament measured after treatment and
baseline MBP in the placebo group.
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121Chapter 6
A comparison of the brain specific proteins and histopathology in post 
mortem multiple sclerosis brain
6.1  Introduction
Although many studies have  investigated CSF BSP in MS,  few (Petzold et al, 
2002;  Bitsch  et  al.,  2000;  Trapp  et  al,  1998;  Ferguson  et  al,  1997)  have 
described how the  BSP relate to histopathological features of the disease.  This 
cross-sectional  study  aimed  (i)  to  investigate  whether  the  markers  for  BSP 
correlate  with  myelin  content,  axonal  count  and  gliosis  as  determined  by 
quantitative  histology  in  post-mortem  multiple  sclerosis  (MS)  brain,  (ii)  to 
evaluate  for differences between BSP within MS normal appearing brain tissue 
(NABT) and lesions.
The following BSP were assessed: ferritin, S100B, GFAP and two neurofdament 
heavy chain phosphoforms  (NfHSM 134 and NfHSM I35).  As previously mentioned, 
ferritin  is  a  marker  for  normal  and  activated  microglia  and  also  a  marker  for 
oligodendrocyte  activity.  It  is  indirectly  involved  in  myelin  production,  as 
oligodendrocytes are the predominant iron-containing cells in the brain.  During 
stress  such as  hypoxia,  oligodendrocytes increase their synthesis of ferritin and 
thereby  protect  cells  against  oxidative  damage  (Cole,  2003;  Arosio  and  Levi, 
2002).  S100B  is  secreted by astrocytes and it is implicated in the regulation of 
cytoskeletal  dynamics  principally  via  protein  phosphorylation  and  cell  cycle
122progression,  most  likely  by  interacting with transcription  factors  and  enzymes 
(Schafer and Heizmann 1996, Donato 1999). GFAP is a useful biological marker 
of astrocytic  activity,  and  it  is  upregulated  in  astrogliosis  (Eng  and  Ghinikar, 
1994).  Finally,  neurofilament  heavy  chain  is  a  highly  phosporylated  axonal 
protein found in all neuronal processes. NfHSM I35 is phosphorylated and NfHSM I34 
is  extensively phosphorylated neurofilament heavy chain (Petzold et al.,  2003). 
Neurofilaments control axonal caliber by forming cross bridges and by interacting 
with microtubules,  thereby preserving the morphological  integrity of axons and 
the conduction velocity of nerve impulses (Al-Chalabi and Miller, 2003).
The  objective  of this  study  was  to  determine  whether  (i)  neurofilaments  and 
S100B  quantified  in  vitro  relate  to  axonal  marker  count;  (ii)  GFAP  (ELISA) 
levels correlate with the extent of gliosis quantified histologically; and (iii) ferritin 
levels relate to myelin content in post-mortem brain tissue of patients with MS.
6.2  Materials and Methods:
Fresh post- mortem brain slices (10mm thick) of 14 subjects with MS (12 women 
and  2  men)  were  obtained from the UK Multiple  Sclerosis Tissue  Bank at the 
Charing Cross Hospital, Imperial College School of Medicine, London, UK. The 
median age (and interquartile range) of the patients was 57  years  (49-73), with 
median disease duration of 29  years (18-34).  The post-mortem interval was 46 
hours (41-59).  Sixty-seven macroscopically visible plagues were sampled along 
with  109  samples  of brain tissue  from normal  appearing grey matter (NAGM;
123n=54)  and  white  matter  (NAWM;  n=55).  The  samples were  homogenized and 
then analysed for BSP using ELISA technique. For the comparison of lesions with 
NAWM  using  BSP  and  histological  techniques,  material  from  lesions  and  the 
adjacent NAWM  were  obtained from  11  MS brain slices  (28  tissue  samples in 
total).  Three  patients  were  excluded  from  this  analysis  because  they  had  no 
macroscopic lesions but all 14 brain slices were used in the subsequent analysis of 
NAWM and lesions using BSP markers alone -  although in the 3 brain without 
lesions, only samples from NABT were obtained).
6.2.1  Protein extraction
Brain tissue (wet weight between  1   and 2  g) were finely cut and suspended in 
barbitone  buffer  containing  0.1%  bovine  serum  albumin.  Samples  were 
homogenized on ice by sonification for 60 seconds. Myelin protein was extracted 
by adding di-isopropyl ether in the proportions of 1:500, centrifuged at 20,000 x g 
and the  lipid layer removed.  The  supernatant was  stored at -80°C until  further 
analysis.  Total  protein  concentration  was  measured  using  the  Lowry  method 
(Peterson 1979).
6.2.2  Brain specific protein analyses
Levels  of  S100B,  GFAP,  ferritin  and  the  two  neurofilament  heavy  chain 
phosphoforms  (NfHSM I35  and  NfHSM B4)  were  quantified  in  brain  tissue 
preparation by sandwich ELISA technique as previously described by Green et al. 
(1997),  Petzold et al.  (2004), Keir et al.  (1993), and Petzold et al.  (2003). The 
dilutions used were as follows:  S100B in a dilution of 1:1000 without EDTA in
124the washing solution, GFAP in a dilution of 1:5000, ferritin in a dilution of 1:100 
and  NfHSM I35  and  NfHSM I34  in  a  dilution  of  1:5000.  All  values  of  BSP  are 
described as ratios to total protein.
6.2.3  Histology studies
The histological studies were performed by Klaus Schmierer. In these, the myelin 
content, extent of gliosis and axonal count in lesions and areas of NAWM were 
assessed. NABT were visually co-registered, in which the brain slice was divided 
using a 5mm deep iron angle with the cut surface corresponding to the centre of 
the MR imaging plane. T2 weighted MRI guidance was used to ascertain NABT 
and  to  record  any  suspected  lesion  on  MRI  that  was  macroscopically  visible. 
Stereotactic co-registration was used for lesions. Tissue blocks of approximately 
2.25cm  in volume and centred on each region of interest (ROI) were dissected. 
The blocks were then cut in half using a 5mm deep iron angle resulting in two 
blocks of equal thickness with the cut surface corresponding to the centre of the 
MR  imaging plane.  The  macroscopically visible  lesion of the tissue  of the  cut 
surface was recorded.
All dissected blocks were marked with a notch at a known position, usually on the 
ventral cut surface (figure 6.1) and processed for paraffin embedment.  Sections 
were  stained with Haematoxylin and Eosin (H&E), Luxol-Fast blue (LFB), and 
Bielschowsky’s silver impregnation (BIEL) (figure 6.2).
125Klaus Schiemerer then classified the tissue sections according to any evidence of
13 lesion  activity,  demyelination  or  remyelination.  The  lesion  stage  was 
categorized as either
1.  Active (inflammation throughout the lesion)
2.  Chronic active (hypocellular centre, inflammation only at the rim of the 
lesion), or
3.  Chronic inactive (no inflammation).
Demyelinated lesions were defined as clearly distinct, sharply demarcated areas 
of myelin  loss  on  LFB  stained  slides.  Remyelinated  lesions  were  defined  as 
clearly  distinct,  sharply  demarcated  areas  with  decreased  intensity  of  LFB 
staining compared to the surrounding NAWM and uniformly think myelin sheaths 
(in relation to axon diameter) throughout the lesion i.e. shadow plagues (Prineas 
et al., 2002).
Klaus  Schmierer counted the axons on BIEL-stained slides using a 21  bar (bar 
length:  13pm) quadrate grid graticule (size:  160pm3) and a final magnification of 
xl250.  Random points were superimposed to lesions and surrounding NAWM. 
On each slide the total number of bars intersecting axons were counted in  12-16 
areas of both the lesion and surrounding NAWM (Bruck et al,  1997). The counts 
were  then  averaged  for  each  lesion  and respective  NAWM  ROI.  The  average 
axon count within the lesions divided by the average axon count in the respective
1 3  The same staging category was previously used by Trapp et al. (1998) and van der Valk and de 
Croot (2000).
126NAWM provided the relative measure of axonal loss for each lesion (expressed in 
percent).
Myelin content was quantified in lesions and NAWM by assessing transmittance 
(Tr), defined as the transmitted light divided by the incident light, on LFB-stained 
sections  using a  Leica  Q500MC  digital  image  analyser with  a 256  grey  scale 
resolution  (Leica  Cambridge  Ltd.,  UK),  which  was  mounted  on  a  Zeiss 
photomicroscope 3 (Carl Zeiss, Jena, FRG). The program was set in RGB mode, 
the  white  level  was  kept  constant  at  75%  of  the  maximum,  and  a  final 
magnification of xl25  was used.  Within every ROI (i.e.  a lesion or an equally 
sized region of using a field size of 400x385pm2) the values obtained from each 
area were averaged, and then divided by the light intensity transmitted through the 
object slide (away from the tissue section) to result in Trmyeiin14 values for lesions 
and NAWM (Nabors et al,  1988; Gentleman et al.,  1999).
Gliosis  in  lesions  and  NAWM  was  classified  on  GFAP-stained  slides 
quantitatively in lesions and the surrounding NAWM in the same manner as for 
myelin content and expressed as TrgIi0sis.
The  thickness  of  LFB-  and  GFAP-stained  sections  was  assessed  using  a 
stereological microscope and a final magnification of xl250. In order to control
14 A high value of Trmyeijn reflects low myelin content.
127for possible systematic errors in the measurements of Tr, on each slide, three to 
five measurements were performed and averaged.
6.2.4  Statistical A nalyses
All  post  mortem  brain  homogenate  analyses  were  performed  with  researchers 
blinded to the histopathology results.  Statistical analyses:  comparisons between 
groups were made with two sample T-tests and relationships between parameters 
were  made  with  Spearman  correlation  coefficients,  using  the  SPSS  software 
package (version  11.0 for Windows).  All levels of BSPs presented are ratios of 
BSP  to  total  protein,  e.g.  ferritinrtotal  protein,  GFAPrtotal  potein,  SlOOBrtotal 
protein, NfHSM 134:total protein and NfHSM I35:total protein. Probability values less 
than  0.05  were  considered  significant.  Multiple  comparisons  were  done  when 
investigating the relationships of BSP, therefore, after Bonferroni’s correction, p 
values of less that 0.01 were considered to indicate statistical significance.
6.3  Results
6.3.1  BSP vs. histopathology (Table 6.1)
Twenty eight brain tissue samples from eleven brain slices were available for BSP 
and  histopathology  quantitative  studies.  Thirteen/28  brain  tissue  homogenates 
from 9 coronal brain slices were obtained from lesions that could be matched with 
13 brain tissue samples from the adjacent macroscopic NAWM. 2/28 brain tissues 
samples from two brain slices were excised from NAWM only.
128GFAP (ELISA) inversely correlated with axonal density (r=-0.51, p=0.01) and the 
number of axons  (r=-0.46, p=0.01) (see table 6.1, figures 6.3 and 6.4). There was 
borderline evidence that S100B inversely correlated with axonal density (r=-0.33 
p=0.09)  (table  6.1).  There  was  no  evidence  of  an  association  between 
neurofilament heavy chain levels  and axonal  density or between neurofilament 
heavy chain levels and axonal count. GFAP did not correlate with the extent of 
gliosis detected histopathologically.
6.3.2  BSP in normal appearing brain tissue vs. lesions
A  total  of  176  brain  tissue  homogenates  were  excised  from  14  post-mortem 
brains.  Sixty-seven  of  the  176  (38%)  brain  tissue  specimens  were  from 
macroscopically  visible  lesions  and  109/176  (62%)  were  from NABT.  Of the 
latter,  55/176  (31%)  constituted  NAWM  and  54/109  (31%)  NAGM.  Fifty 
seven/176  (32%)  samples  of lesions  were  excised  from  the  white  matter  and 
10/176 (10%) from the grey matter.
Table  6.2  illustrates  that  ferritin  levels  was  highest  in  NABT  and  lowest  in 
lesions, particularly lesions in the grey matter The ferritin levels in grey matter 
lesions is significantly lower than the levels in NAWM, NAGM and WM lesions 
(all p values <0.01).
Higher levels of S100B were detected in white matter in comparison to GM, with 
the highest levels in macroscopically detectable WM lesions and the lowest level
129in GM lesions.  This astroglial protein was sevenfold higher in WM lesions than 
in  GM  lesions  (p-value<0.001).  There  was  no  significant  difference  between 
levels of S100B in macroscopically normal white matter and WM lesions.
Similarly,  levels  of GFAP  (ELISA) were highest in WM lesions  and lowest in 
GM lesions. However, the difference between GFAPs levels in WM lesions and 
NAWM was nearly threefold (p<0.05).
There was no significant difference in NfHSM I34 and NfHSM I35 levels in NABT and 
macroscopically detectable lesions.
6.3.3  Relationships between BSPs (ELISA) (Table 6.3)
In NAGM and NAWM, S100B is associated with ferritin (r=0.65 p<0.01, r=0.49 
p<0.01) and GFAP (ELISA) (r=0.40 p<0.01, r=0.49 p<0.01  respectively). There 
is  also  evidence  that  in  NABT,  ferritin  correlates  with  GFAP  (ELISA)  and 
NfHSMI  (r=0.65  p<0.01,  r=0.51  p=<0.01  (in  NAGM);  r=0.47  p<0.01,  r=0.6 
p<0.01  (in  NAWM)),  and  that  the  axonal  marker  NfHSM I34  correlates  with 
N fH SMi35 (j^ q.49 p<0.01 (in NAGM); r=0.54 p<0.01 (in NAWM)).
In WM  and GM lesions,  the astroglial marker S100B  is associated with GFAP 
(ELISA). Similar to NABT, ferritin correlates with GFAP (ELISA) and NfHSM I34 
in  white  matter  lesions  (r=0.50  p<0.01,  r=0.41  p<0.01  respectively).  In  GM 
lesions, NfHSM I34 correlates with NfHSM D 5 (r=0.83 p<0.01).
1306.4  Discussion
This  study suggests that axonal loss in MS as measured using histopathological 
techniques is more pronounced in the vicinity of reactive gliosis as measured via 
ELISA though there was no evidence suggesting this by using histology alone. 
S100B, an astrocytic protein, was also more abundant in regions of axonal loss. 
However,  neurofilament  heavy  chain  levels  did  not  correlate  with  the  axonal 
count and density; GFAP (ELISA) did not correlate with the extent of gliosis; and 
ferritin  was  not  associated  with  myelin  content;  possible  reasons  for  these 
negative  results  will  be  discussed  below.  Of note,  BSP  were  able  to  detect 
differences  between  GM  and  WM  (ferritin)  and  between  lesions  and  normal 
appearing  brain  tissue  in  GM  (ferritin  and  S100B)  and  in  WM  (GFAP  and 
NfHSM IM ).
The  presence  of axonal  injury  in  the  vicinity  of reactive  gliosis  is  intriguing. 
Astrocytic  proliferation  and  astrogliosis  occur  in  response  to  CNS  insult 
(Penkowa et al.  2003; Eng et al.,  2000), and acute inflammatory changes in MS 
lesions are associated with axonal transection (Trapp et al,  1998).  However the 
areas of astrocytic activation as indicated by the GFAP levels were predominantly 
in  WM  lesions,  less  in  NAWM,  and  less  in  the  grey  matter.  Therefore  one 
possible explanation for the link between GFAP and axonal density is that acute 
inflammatory  insult  results  in  both  processes.  The  histological  analysis  of the 
samples  used  for this  study has  shown that the  extent of gliosis  did not differ 
between lesions and NAWM (Schmierer et al., 2004), rather that fibrillary gliosis
131was present throughout MS  white matter (Allen et al,  2001;  Schmierer et al, 
2004). Further studies are required to resolve these conflicting findings.
We have also found abundant ferritin in the NAGM and particularly low levels in 
lesions.  In normal  adult human brain tissue,  the total  ferritin concentration has 
been analyzed separately in white and grey matter from the cerebrum and there 
are  no  marked  differences  between  the  two  tissues  (Connor et al  1992).  It  is 
mainly contained within oligodendrocytes (Gerber and Connor,  1989; Gelman et 
al 1992; Kaneko et al,  1989; Bradbury, 1997) but is also a marker for normal and 
activated  microglia.  It  is  also  significantly  elevated  in  the  CSF  of  chronic 
progressive active MS patients i.e. patients who had deterioration of their disease 
status within the past 12 months, compared to normal individuals (Levine  1999), 
and the elevated ferritin levels in normal brain tissue could be a possible defense 
mechanism to protect against iron induced oxidative damage Cole, 2003; Arosio 
and Levi, 2002). We have also observed elevated ferritin in GM in comparison to 
WM (both in lesions and normal appearing brain tissue). Possible reasons for this 
include that ferritin iron contributes to the neurodegenerative pathway of MS i.e. 
increased  toxicity,  which  is  also  seen  in  Parkinson’s  disease  and  Alzheimer’s 
disease (Bartzokis et al, 2004). In vivo MRI that measure and track brain ferritin 
iron level is required to confirm this finding (Bartzokis et al, 2004).
The presence of S100B in CSF is normally due to an immediate release from the 
cytosol of astrocytes and an upregulation of its release has been implicated as an
132index of CNS injury (Petzold et al, 2003). A high concentration of this astrocytic 
protein  is  seen in  subarachnoid haemorrhage,  rapid parenchymal  destruction in 
epilepsy, Creutzfeldt-Jakob disease, acute brain injury, compression of the spinal 
cord by space-occupying lesions, ischaemic disorders and viral or suspected viral 
infection  (Donato  2001,  Sindic  1982).  We  have  found a high  concentration  of 
S100B  in  white  matter  lesions  and  a  significantly  lower  level  in  grey  matter 
lesions. Of note, GM lesions have been shown to be less inflammatory than WM 
lesions  and  difference  in  the  pathology  between  GM  and  WM  lesions  might 
explain the differences in GFAP that we have observed (Bo et al, 2003a; 2003b; 
2004).
Significantly  higher  levels  of extensively  phosphorylated  neurofilament  heavy 
chain  (NfHSM I34)  are  found  in NAWM  compared to  white  matter lesions.  This 
supports the hypothesis that axons are healthier within NABT compared to axons 
traversing lesions (Lim et al, 2004).
The  lack  of  a  correlation  between  neurofilaments  and  axonal  count;  GFAP 
(ELISA)  and  gliosis,  and  ferritin  and  myelin  content  may  be  due  to 
methodological limitations of this study. The MS lesions were not sampled using 
MRI-guidance, the tissue block is 5mm below the site of tissue sampling, and a 
proportion  of  abnormalities  detected  by  post-mortem  MRI  may  not  be 
macroscopically visible (van Waesberghe et al,  1999; Bo et al, 2004). The brain
133slices  were  also  not  from  the  same  anatomical  region  and  this  will  almost 
certainly have confounded our results.
In  conclusion,  this  study  has  shown  a  relationship  between  GFAP  levels  as 
measured by ELISA  and the degree of axonal  loss  detected in the  same tissue 
sample. In addition, GFAP was elevated and NfHSM I34 reduced in WM lesions in 
comparison  to  NAWM.  These  data provide  further evidence  for a  relationship 
between axonal injury and reactive gliosis.
134Figure 6.1  Brain slice indicating ventral and dorsal sides with arrow pointing 
to  plaques  which  were  sampled  on  either  side.  Adjacent  NABT  were  also 
sampled.
135Figure 6.2  MRI  T2-weighted image  (a) was  done  5mm beneath the  surface 
where samples were excised. This brain slice revealed 5 arears of high signal on 
T2-weighted MRI (b-d). All the bluish images are stained for Luxol fast blue to 
visualise myelin (f,g). The demyelinated lesion as shown on the right was stained 
for GFAP  for  gliosis(h,i)  and  Bielschowsky‘s  silver stain  for axons  (j-L).  The 
section in the right comer is magnified for counting of axons (L).
(See next page)
136Variables Axonal density Axonal lesion 
count
Myelin content Area of 
gliosis
NfflSMI34 r=0.06 r=0.07 r=-0.11 r=0.05
p=0.77 p=0.72 p=0.58 p=0.82
NfHSM I35 r=-0.04 r=-0.05 r=0.11 r=0.18
p=0.85 p=0.82 p=0.58 p=0.38
Ferritin r=0.08 r=0.10 r=-0.23 r=0.29
p=0.70 p=0.62 p=0.25 p=0.15
S100B r=-0.33 r=-0.30 r=0.11 r=0.23
p=0.09 p=0.12 p=0.57 p=0.25
GFAP r=-0.50 r=-0.46 r=0.43 r=0.04
p=0.01a p=0.01b p=0.02c p=0.86
Table 6.1  Spearman  rank  correlation  coefficients  were  used  to  examine 
associations between brain specific proteins and quantitative histology.
a,b,c  Significant P value is taken at  0.05 level
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Figure 6.3  Scatterplot of GFAP versus axonal count in normal appearing white matter 
and lesions.
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Figure 6.4  Scatterplot  of GFAP  versus  axonal  density  in  normal  appearing  white 
matter and MS lesions.
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12-33)
n=55
11
(6-30)
n=54
22
(5-41)
n=56
13
(11-18)
n=10
Table 6.2  Brain  specific  proteins  to  total  protein  ratios  in  multiple  sclerosis  brain 
tissues [median (interquartile range, number)]. All values have been multiplied by 104. 
Significant P value is taken at 0.05 levels.
141SIOOB Ferritin GFAP NfH
SMI34
NfH  Ferritir
SMI35
GFAP NfH
SM134
NfH  GFAP
SMI35
NfH
SMI34
NfH  NfH
SMI35  SMI34
NfH
SM135
NAGM r=0.65 r=0.49 r=0.30 r=0.09 r=0.65 r=0.51 r=0.07 r=0.38 r=0.28 r=0.49
p=0.00 p=0.00 p=0.03 p=0.51 p=0.00 p=0.00 p=0.64 p=0.01 p=0.04 p=0.00
n=45 n=53 n=52 n=53 n=45 n=45 n=45 n=52 n=54 n=52
NAWM r=0.40 r=0.49 r=0023 r=0.35 r=0.47 r=0.60 r=0.45 r=0.30 r=0.39 r=0.54
p=0.01 p=0.00 p=0.09 p=0.01 p=0.00 p=0.00 p=0.00 p=0.03 p=0.00 p=0.00
n=46 n=55 n=55 n=55 n=46 n=46 n=46 n=55 n=55 n=55
WM r=0.16 r=0.38 r=0.23 r=-0.04 r=0.50 r=0.41 r=0.25 r=0.26 r=0.22 r=0.16
lesions p=0.28 p=0.00 p=0.10 p=0.77 p=0.00 p=0.00 p=0.08 p=0.07 p=0.10 p=0.27
n=51 n=55 n=51 n=56 n=50 n=51 n=51 n=50 n=55 n=51
GM r=-0.46 r=0.82 r=0.24 r=-0.06 r=-0.27 r=0.32 r=0.37 r=0.42 r=0.10 r=0.83
lesions p=0.19 p=0.00 p=0.51 p=0.88 p=0.45 p=0.37 p=0.29 p=0.23 p=0.78 p=0.00
n=10 n=10 n=10 n=10 n=10 n=10 n=10 n=10 n=10 n=10
Table 6.3  Non  parametric  Spearman  associations  between  different  brain  specific  protein  to  total  protein  ratios  in  NAGM, 
NAWM, lesions in WM and lesions in GM.
After Bonferroni’ s correction, p values < 0.01 is taken as significant 
Highlighted values are statistically significantPART 3
SPECIFIC MARKERS IN PROGRESSIVE 
DISEASE AND CLINICALLY ISOLATED 
SYNDROMES
143Chapter 7
Serum S100B in primary progressive multiple sclerosis 
patients treated with interferon-beta-la
7.1  Introduction
This  study  of serum  S100B  in PPMS  is based  on data obtained 
from a randomized,  controlled trial of Interferon p-la in subjects 
with  PPMS.  The  key questions were whether S100B  levels were 
associated  with  either  disability  or  MRI  findings  in  PPMS  and 
whether Interferon p-la has an effect on their S100B levels. So far 
these  questions  have  been  answered with regards  to  RRMS  and 
SPMS, and as yet, not with PPMS.
Several studies suggest that S100B has a role in the pathogenesis 
of multiple  sclerosis.  Phenotypically  and  functionally  similar  T 
cells specific against S100B can be detected in the peripheral blood 
of MS patients making S100B a putative candidate auto-antigen in 
MS (Schmidt,  1998).  Furthermore,  S100B may act as a cytokine 
(Donato, 2001; Massaro et al,  1985; Michetti et al.,  1980) and in 
vitro  studies  show  that,  at  high  levels,  SI00  can  induce  the 
neuronal expression and secretion of pro-inflammatory interleukin-
6.  In addition, elevated levels of S100B have been detected in the 
CSF  of MS  patients  during acute phases  or exacerbations of the
144disease (Massaro et al,  1985) and it has therefore been proposed 
that  elevated  S100B  may  be  indicative  of  active  cell  injury 
(Michetti et al.,  1980).
Interferon-p  is  effective  in  reducing relapse  rate  in  RRMS (The 
INFB  Multiple  Sclerosis  Study Group,  1993; Jacobs et al.,  1996; 
PRISMS  Study Group,  1998) and SPMS (European Study Group 
on IFNB,  1998) but the mechanisms behind the beneficial action of 
IFNP are not fully understood.  Two potential sites of action are on 
cytokine production (Dayal et al.,  1995; Gayo et al.,  1999; Panitch 
et al,  1987) and on the entry of leukocytes into the CNS (Leppert 
et al.,  1996; Lou et al.,  1999; Stuve et al.,  1996; Uhm et al.,  1999).
7.2  Aims
In this clinically negative phase II study (Leary et al.,  2003); the 
aim was to assess the effect of IFNp-la on serum levels of S100B 
at  3-month  intervals  in  subjects  with  primary  progressive  MS 
(PPMS).  The  key  questions  were  whether  serum  S100B  levels 
correlated with disability or MRI findings in patients with PPMS, 
and whether IFN- p has an effect on levels of serum S100B.
7.3  Methods
7.3.1  Patients and examination
145Fifty patients with PPMS were recruited in a phase II trial of IFNji- 
la  (Avonex®,  Biogen)  and were assessed three monthly over a 
study period of 2 years. Fifteen of these patients were treated with 
IFNp-la 30p.g intramuscularly (im) weekly (IFN30),  15  received 
IFN^-la 60pg im weekly (IFN60) and 20 with placebo. IFNfi-la 
was reduced to half dose in 5 subjects receiving 60p,g im weekly, 
and  in  2  subjects  receiving  IFNfl-la  30pg  im  weekly.  Seven 
subjects withdrew from treatment (Leary et al, 2003) (Figure 7.1).
Neurological  examination  was  performed  at  each  visit  and 
disability was measured using Kurtzke’s expanded disability status 
scale  (EDSS).  Progression was defined as a sustained (3  months 
apart) increase of at least 1.0 on the EDSS scale between 0 to 5 and 
0.5 for subjects with EDSS score of 5.5 and above.
Fourteen healthy subjects served as controls.
7.3.2  MR imaging and analyses
MRI was performed at baseline and 6 monthly for 2 years.  Only 
baseline  and  year  2  data  were  included  in this  study.  Brain and 
spinal  cord  atrophy,  ventricular  volume,  T1  and  T2  lesion  load 
were measured as described in Leary et al. [2003] study.
1467.3.3  Serum SIOOB levels
Serum  samples  were  centrifuged  and  stored  at  -20°C.  Semm 
S100B levels were quantified using a modified ELISA method as 
described in chapter 3.
7.3.4  Statistical analyses
Median,  interquartile range and significance of group differences 
(Mann-Whitney U tests) were evaluated. Changes of serum level 
over  time  were  examined  using  variance  components  regression 
models  of  serum  response  variable  on  time  as  predictor,  with 
random  subject-specific  intercepts  and  fixed  common  slopes. 
Curvature  was  assessed  using  a  quadratic  term  in  time; 
modification of curve over time by treatment was assessed using 
additional terms for treatment and treatment by time interaction in 
the model.  Two sets of treatment terms were used: i) indicators of 
assigned  weekly  dose  ii)  average  weekly  dose  over  follow-up 
(including  changes  to  dose  regime)  as  continuous  variable. 
Modification of the curve over time by MRI variable values were 
similarly examined using terms for MRI variable and MRI variable 
by time interaction.
Direct associations between serum level and MRI/clinical variables 
were  examined  by  regression models  of 24  month  semm  on 24
147month MRI variable, adjusting for baseline serum and MRI values 
(this type of model takes into account change from baseline), with 
additional  terms  for  treatment  and  treatment  by  MRI  variable 
interaction,  the  latter  to  assess  possible  modifications  of  the 
relationship by treatment.
Softwares used were the SPSS software package (version 11.0 for 
Windows) and Stata 7.0 (Stata Corporation, 2001).
7.4  Results
7.4.1  Serum SIOOB between subjects with PPMS and controls 
The median and interquartile ranges for all subjects are described 
in Table 7.1. There were no significant differences between any of 
the  groups  in  relation  to  age.  When  comparing  S100B  levels  at 
baseline  of subjects  with PPMS  and controls, the difference was 
not statistically significant (p=0.3).
7.4.2  Serum SIOOB change over time (Figures 7.2,  7.3 and 7.4) 
There  was  no  change  over time  in the  serum  S100B  levels.  The 
shape of the  serum trajectory did not vary between the treatment 
regimes, i.e. placebo vs. IFN30 vs. IFN60.
7.4.3  Serum SIOOB versus  Clinical and MRI parameters (Table 
7.2)
148There  was  no  evidence  that  the  24-month  serum  SIOOB  values 
were  associated  with  either  changes  in  the  T1  or  T2  loads,  or 
ventricular or cord volumes at 24 months,  after adjusting for the 
baseline  values  of each  subject.  There  was  no  correlation  with 
disease progression on the EDSS. There was also no evidence that 
these  relationships  were  modified  by  treatment  assignment 
(intention-to-treat analysis) (Table 7.2) or the overall average dose, 
which included the changes to treatment regime (non-intention-to- 
treat analysis) (Table7.2).
7.5  Discussion
These  results  suggest  that  serum  SIOOB  levels  in  patients  with 
PPMS were not affected by intramuscular IFNP-la and that there 
was  no  observable  change  in  SIOOB  over time.  Furthermore,  we 
did not observe any correlation between SIOOB levels and clinical 
disability or between SIOOB and quantitative MRI measures.
This  study  therefore  suggests  that  serum  SIOOB  would  be 
ineffective as a surrogate marker in PPMS. In addition, as there is 
evidence  that  SIOOB  elevation in  MS  is related to  inflammatory 
activity (Massaro et al.,  1985; Michetti et al.,  1980; Petzold et al., 
2002a),  this  study  has  shown  that  S100B  was  not  sensitive  to
149disease progression in PPMS.  This adds weight to the view that 
PPMS is less inflammatory.
Nonetheless it is necessary to devise surrogate markers in PPMS to 
aid  the  development  of  effective  therapeutic  intervention.  It  is 
possible that such markers would need to be less related to acute 
inflammation  and  dependent  on  other  neuropathology  such  as 
axonal loss and regeneration.
150Figure 7.1  Fifty subjects with PPMS were randomised in a phase II trial 
of Interferon 0-1 a and were assessed 3 monthly over a 2-year study period. 
n=number of subjects with PPMS
Placebo < d=2i0 i)
Randomized |n=54}>
Follow up 2 years. 
*11=14)
Follow up 2 years. Follow up 2 years 
<n-2*)
Treatment withdrawal 
______ (n=2)__________
Treatment withdrawal 
<n=4)
D«s« reduction 
*n=5)
Treatment withdrawal
(n*l.)
Dose reduction
(n=2)
151Control Placebo IFN30 IFN60
(n=14) (n=20) (n=15) (n=15)
Male: Female 6:8 15:5 10:5 7:8
n=14 n=20 n=15 n=15
Age (years) 32 43 51 52
(29-44) (36-51) (39-53) (43-54)
n=14 n=20 n=15 n=15
SIOOB-Omo 0.08 0.09 0.06 0.07
(0.08-0.10) (0.02-0.10) (0.04-0.10) (0.04-0.10)
n=14 n=20 n=12 n=14
S100B-3mo N/A 0.08 0.06 0.07
(0.05-0.10) (0.05-0.10) (0.04-0.10)
n=20 n=15 n=14
S100B-6mo N/A 0.10 0.07 0.07
(0.03-0.20) (0.04-0.10) (0.04-0.10)
n=18 n=15 n=14
S100B-9mo N/A 0.08 0.05 0.06
(0.03-0.10) (0.02-0.10) (0.04-0.10)
n=18 n=15 n=14
S100B-12mo N/A 0.07 0.08 0.08
(0.03-0.10) (0.05-0.10) (0.04-0.10)
n=17 n=15 n=14
S100B-15mo N/A 0.07 0.07 0.09
(0.02-0.10) (0.04-0.10) (0.04-0.10)
n=19 n=14 n=14
S100B-18mo N/A 0.07 0.06 0.09
(0.04-0.10) (0.02-0.09) (0.03-0.20)
n=18 n=13 n=14
S100B-21  mo N/A 0.06 0.08 0.08
(0.05-0.10) (0.04-0.10) (0.04-0.20)
n=18 n=14 n=13
S100B-24mo N/A 0.07 0.07 0.06
(0.02-0.10) (0.05-0.10) (0.04-0.10)
n=18 n=15 n=13
Table 7.1  Age and serial serum SIOOB levels expressed as median 
(interquartile range).
n=number of subjects; mo, months; N/A, non-applicable.
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Figure 7.2  Three-monthly serum SIOOB levels trajectory of each 
subject with PPMS who were given placebo weekly for 2 years.treatment=30
month
Figure 7.3  Three-monthly serum SIOOB levels trajectory of each 
patient  with  PPMS  who  received  IFNp-la  30pg  intramuscularly 
weekly for 2 years.treatment=60
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Figure 7.4  Three-monthly serum SIOOB levels trajectory of each 
patient  with  PPMS  who  received  IFNfS-la  60pg  intramuscularly 
weekly for 2 years.Serum S1OOB versus Clinical and MRI variables
Variable Coefficient P-value 95% Confidence 
Interval (Cl)
P-value for 
treatment 
modification : 
Assignment 
average dose
24 month T1 
load
-4x1O'6 0.35 -lxlO'5,4xl0'6 0.76  0.59
24 month T2 
load
-3x1 O'6 0.16 -7x1 O'6, 1  x 1  O'6 0.57  0.89
24 month
ventricular
volume
7x1 O'7 0.75 -3x1 O'6, 5X10-6 0.46  0.24
24 month cord 
volume
-2x1 O'3 0.54 -9x1 O'3, 5xl0'3 0.58  0.88
Table 7.2
Estimated  mean  change  in 24-month  serum  SIOOB  associated with unit 
increase  in mean value  of T1  and T2 lesion load, ventricular and spinal 
cord  volume,  adjusted  for baseline  values  of both  serum  SIOOB  and  of 
MRI parameters.  Baseline adjustment ensures that the coefficient assesses 
the ‘effect’ of the 24-month MRI parameters value relative to its baseline.
*
Test of treatment interactions with row variable.
156Chapter 8
Do anti-myelin antibodies allow earlier diagnosis of multiple
sclerosis?
8.1  Introduction
Recently, Berger et al  (2003) have determined that in a cohort of 
patients  with CIS,  and  an abnormal  MRI  study at baseline,  who 
were seropositive for the anti-myelin antibodies, had more frequent 
relapses  than  those  who  were  seronegative,  and  that  these 
antibodies predicted the conversion to MS (Berger et al., 2003).  In 
collaboration  with  Berger  and  colleagues  (Department  of 
Neurology,  University  of  Innsbruck,  Austria),  this  study 
investigated  whether  the  presence  of  anti-MBP  and  anti-MOG 
antibodies in the peripheral blood would predict conversion to MS 
according to the McDonald (2001) and Poser (1983) criteria, in a 
separate cohort of patients with CIS.
A possible pathogenetic mechanism responsible for conversion of 
a CIS to CDMS is antibody-mediated demyelination. MBP is one 
of the most important proteins of the myelin sheath, and MOG is 
exclusively  expressed  at  the  outer  surface  of myelin  sheath  and 
oligodendrocyte plasma membrane (Brunner,  1989).  Enhanced T- 
and  B-cell  responses  to  MBP  and  MOG  has  been  reported  in 
multiple  sclerosis  (MS)  (Reindl  et  al,  1999;  Egg  et  al,  2001;
157Kerlero de Rosbo et al.,  1990; Xiao et al.,  1991; Sun et al.,  1991; 
Wallstrom et al.,  1998), but the role of these responses in disease 
pathogenesis is uncertain.
8.2  Aims
The objective of this study is to determine whether the presence of 
serum and plasma antibodies against MOG and MBP in patients 
presenting  with  a  CIS  compatible  with  demyelination  predicts 
early conversion to MS.
8.3  Methods
8.3.1  Patients
Patients  with  CIS  were  recruited  from  either  Moorfields  Eye 
Hospital or the National Hospital for Neurology and Neurosurgery, 
London. A CIS was defined as a single event of acute onset in the 
central nervous system suggestive of demyelination. The diagnosis 
of MS was based on the new McDonald MRI criteria (2001) and 
CDMS  using the  more  established Poser criteria (1983).  Clinical 
and MRI assessments were done less than 3 months from clinical 
onset, and again after 3 months and 1   year (patients are also being 
followed at 3  years but 3  year data is not included in this report 
because  of  the  small  number  who  had  anti-myelin  antibody 
testing).  The  design of this prospective CIS  follow-up  study and
158the protocol  for clinical examination and MRI investigations has 
been described in detail elsewhere (Dalton et al., 2002).
8.3.2  Antimyelin antibody analysis
Blood samples were centrifuged and stored at -80°C. Berger and 
colleagues had analysed the anti-MOG and anti-MBP antibodies in 
their  laboratory  using  western  blotting  as  previously  described 
(Reindl  et  al.,  1999;  Egg et al.,  2001) with minor modifications 
(Berger et al., 2003).
8.3.3  Statistical A nalysis
All  blood  tests  were  performed  with  researchers  blinded  to  the 
clinical  diagnosis  and  MRI  results.  Statistical  analyses  were 
evaluated  using  the  SPSS  software  package  (Version  11.0  for 
Windows).  The  characteristics  of  the  patients,  their  clinical 
disability  and  MRI  measures  according  to  their  antibody  status 
were compared using median, interquartile range and Fischer rank 
exact  test.  The  relative  risk  of  the  development  of  clinically 
definite  MS  was  measured  using  Cox-regression.  Probability 
values less than 0.05 were considered significant.
8.4  Results
A  total  of forty-seven patients had baseline  anti-MOG  and anti- 
MBP  antibodies  analyzed.  Thirty-five  of the  47  patients  were
159female and  12 were male; their median age at the onset of disease 
was  31  years  (28-36).  Forty-six  of the  patients  presented  with 
clinically isolated ON and 1  patient had spinal cord syndrome. The 
median EDSS score was 1.0 (1.0 to 1.0). The characteristics of the 
patients  and  their  disease  are  shown  in  Table  8.1.  All  47  were 
followed up after 3 months and 35 after one year.
Thirteen/47 patients (27.7%) were seropositive for both anti-MOG 
and  anti-MBP  antibodies,  13  (27.7%) were  seropositive  for only 
anti-MOG antibodies,  11  (23.4%) were seropositive for anti-MBP 
antibodies alone and  10 (21.3%) were seronegative for both anti- 
MOG and anti-MBP antibodies.
Table 8.2 shows the number of patients who converted to MS at 3 
months and 12 months based on both McDonald and Poser criteria. 
After 3  months,  13/47 (28%) had developed MS according to the 
McDonald criteria; after one year, 20/35 (57%) had MS. Tables 8.3 
and  8.4  illustrate  the  cumulative  total  that  converted  to  MS 
compared  to  those  that  did  not  according to  the  McDonald  and 
Poser criteria respectively at 3 and 12 months.
Antibody status  does not relate to the patients who  subsequently 
developed  MS  or  CDMS  according  to  either  the  McDonald  or 
Poser  criteria  respectively.  Furthermore,  Cox-regression  analysis
160(Figure 8.1) showed that antibody status did not predict risk of MS 
(p=0.27).
Thirteen of the 47 patients had normal baseline T2-weighted MRI 
brain.  Five/13  (38.5%)  were  seropositive  for  both  anti-myelin 
antibodies,  4 (30.8%) had antibodies against MOG and  1   (7.7%) 
had antibodies against MBP. Three of the  13 patients (23%) were 
seronegative for both antibodies.
There was no evidence that antibody status related to T2-weighted 
or  gadolinium  enhanced  brain  or  spinal  cord  MRI  findings  at 
baseline, or with new MRI lesions at 3 months and  1   year. There 
was no association between antibody status and EDSS assessed at 
baseline.
8.5  Discussion
This  study  shows  that  anti-myelin antibodies  did not predict the 
development  of  MS  or  CDMS  within  one  year  after  a  first 
demyelinating event in this cohort of CIS patients. There was also 
no  association  between  antibody  status  and  baseline  clinical  or 
MRI variables.
161Although  this  study  is  relatively  small,  recruitment  was 
prospective  and  based on clinical  findings  alone  (thus  including 
subjects  with  a  normal  MRI).  Analysis  of  serum  was  also 
performed  blinded  to  clinical  and  MRI  findings.  A  limitation  is 
that  follow  up  was  for  only  12  months;  however  the  new 
McDonald  criteria  were  used,  which  increased  the  rate  of early 
diagnosis  such  that  57%  had developed MS  after one  year.  The 
McDonald  criteria  incorporate  the  surrogate  MRI  markers  in 
predicting conversion  from CIS to MS,  and have been  shown to 
have a high specificity for the subsequent development of CDMS 
(Dalton et al., 2002; Tintore et al., 2003). The old Poser criteria for 
diagnosing CDMS were employed in parallel for comparison and 
yielded  similar  lack  of  association  with  anti-myelin  antibody 
findings.  The  same  method  was  used  for  detecting  anti-myelin 
antibodies  as  was  reported  in the  original  study of Berger et  al 
(2003).
Although  this  study  did  not  reproduce  the  original  findings 
reported by Berger et al.  (2003), there are differences between the 
study design e.g. patients with a normal baseline MRI study were 
included and the follow-up is of a shorter duration of time.  This 
study was also confined, with a single exception, to patients with 
isolated ON; one cannot exclude the possibility that different anti­
162myelin  antibody  profiles  might  occur  in  other  CIS  cohorts  e.g. 
isolated brain stem or spinal cord syndromes. Of note, the results 
remain  unchanged  when  the  one  patient  with  clinical  isolated 
spinal  cord  syndrome  who  is  seronegative  for  both  anti-myelin 
antibodies is excluded from the cohort.
Nevertheless,  the findings do, however, raise doubt whether anti- 
MOG and anti-MBP antibodies will prove to be reliable as markers 
of  prognosis  and  also  question  whether  these  antibodies  are 
involved  in the  early pathogenesis of MS.  On the  contrary this 
study has found no evidence that the antibody status related to the 
early disease course or to changes in MRI measures in brain and 
spinal cord at 3 and  12 months. Further studies in other early MS 
or CIS cohorts are recommended.
163Variable Negative for 
Anti-MOG 
and Anti- 
MBP
Positive for 
Anti-MBP
and
Negative for 
anti-MOG
Positive for 
Anti-MOG 
and Negative 
for Anti-MBP
Positive 
for Anti- 
MOG and 
Anti- 
MBP
No. of patients 10 11 13 13
Female sex -no. (%) 8(80) 8(73) 9(69) 10(77)
Age -  yrs 33
(30-38)
33
(27-35)
28
(25-36)
31
(29-37)
Types of symptoms 
at presentation  -  
no. (%)
Optic neuritis 
Spinal cord syndrome 9(90) 11 (100) 13 (100) 13 (100)
1(10) 0(0) 0(0) 0(0)
Median no. of lesions on 
T2-weighted MRI brain 
at baseline
18
(0-33)
4
(3-45)
1
(0-10)
5
(0-11)
Median no. of lesions on 
Tj-weighted gadolinium 
enhanced MRI
0
(0-2)
1
(0-2)
0
(0-0)
0
(0-1)
Median no. of lesions on 
T2-weighted MRI spinal 
cord at baseline
0
(0-0)
1
(0-4)
0
(0-0.5)
0
(0-0)
Clinical disability
EDSS=0
EDSS=1
EDSS=1.5
EDSS=2
1  (10) 1(9) 1(8) 0(0)
9(90) 10  (91) 11(84) 10 (77)
0(0) 0(0) 0(0) 1(8)
0(0) 0(0) 1(8) 2(15)
Table 8.1
Characteristics  of  the  47  patients  and  their  disease,  according  to  the 
antibody status.
164McDonald MS Poser MS
Follow-up Positive Negative Positive Negative
3 months (n=47) 13(28) 34 (72) 3(6) 44 (94)
12 months (n=35) 20 (57) 15(43) 9(32) 26 (74)
Table 8.2  Conversion to clinically definite multiple sclerosis according 
to McDonald and Poser criteria.
MS=multiple sclerosis; n=number of patients.
165Follow-up McDonald MS Poser MS
Positive Negative Positive Negative
3 months  (n=47) 13 (28) 34 (72) 3(6) 44(94)
12 months (n=35) 20 (57) 15 (43) 9(26) 26 (74)
Cumulative total 
who converted to 
MS at following 
time-points
3 months 12 months 3 months 12 months
Positive 
n=13 (28%)
Positive 
n=20 (57%)
Positive 
n=3 (6%)
Positive 
n=9 (26%)
Cumulative no. with 
anti-MBP ab alone
4(31) 5(25) 2(67) 2(22)
Cumulative no. with 
anti-MOG ab alone
2(15) 3(15) 0(0) 1(11)
Cumulative no. with 
both antibodies
3(23) 5(25) 0(0) 2(22)
Cumulative no. 
without antibody
4(31) 7(35) 1(33) 4(44)
Table 8.3
Conversion  to  clinically  definite  multiple  sclerosis  according  to 
McDonald  and  Poser  criteria  and  the  cumulative  total  that 
converted to MS compared to those that did not according to each 
criteria.
No., n=number of patients; ab=antibody
166C
u
m
 
H
a
z
a
r
d
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168Chapter 9 
Summary and Conclusions
The thesis looks at whether brain specific proteins have any role as 
potential surrogate markers in demyelinating diseases, in particular 
multiple sclerosis.
The first study consists of 41  subjects who had acute ON and  17 
subjects  with  other  neurological  diseases  served  as  controls. 
Twenty one  subjects  with  ON  had white matter lesions  on  MRI 
and intrathecal synthesis of oligoclonal IgG bands consistent with 
being at high risk of progression to MS; eight of whom later were 
diagnosed  with  CDMS.  Levels  of  SIOOB,  ferritin  and  two 
neurofilament heavy chain phosphoforms (NfHSM I34 and NfHSM I35) 
were analysed using ELISA technique. A putative index of ‘axonal 
health’ was expressed as a ratio of NfH SM I34 to NfH SM I35. NfHSM I34 
and the NfH SM 134 SM I35 were significantly elevated in subjects with 
ON  compared to controls. No significant differences  in levels of 
CSF BSP were seen between ON subjects with CDMS plus those 
at high risk of progression to  MS and ON  subjects with normal 
MRI and negative CSF analysis. In conclusion, there is evidence of 
axonal  damage  in  subjects  who  present  with  ON,  which  is 
independent of the diagnosis of CDMS.
169The findings of the next study are CSF neurofilament heavy chain 
levels, thought to be markers of axonal pathology, predict clinical 
outcome  and correlate with gadolinium enhancing lesion volume 
and  CSF  MBP  in  subjects  with  ON  and  MS.  Again  the  study 
supports the view that acute inflammation in ON and MS results in 
axonal  pathology  and  that  the  latter  has  a  role  in  determining 
functional impairment.
The  third  study provides  preliminary evidence  for a relationship 
between  axonal  injury  and  reactive  gliosis.  The  data  shows  a 
relationship between GFAP levels as measured via ELISA and the 
degree  of  axonal  loss  detected  in  the  same  tissue  sample.  In 
addition, GFAP was elevated and NfHSM D 4 reduced in WM lesions 
in comparison to NAWM. Further studies are required to confirm 
these findings.
In  Part  3,  serial  serum  SIOOB  levels  were  measured  using  an 
ELISA method. The results demonstrated that serum SIOOB is not 
related to  either disease progression or MRI findings  in subjects 
with primary progressive MS given Interferon  0-1 a.  Furthermore 
there is no correlation between SIOOB levels and the primary and 
secondary outcome measures.
170The  final  study shows that anti-myelin antibodies  do not predict 
conversion to multiple sclerosis. In view of previous positive study 
by Berger et al. 2003, further studies should be done to clarify this 
issue.
In  conclusion,  acute  inflammatory  demyelination  (optic  neuritis 
and multiple sclerosis) is associated with acute axonal damage and 
loss which supports previous pathology work by Trapp et al.  1998. 
Furthermore,  axonal  markers  such  as  neurofilaments  predicts 
clinical  outcome  and  ongoing deterioration  in patients  with  MS. 
Axonal  changes  occur  in  the  vicinity  of gliosis  indicating  that 
inflammation,  demyelination and repair are closely linked.  In the 
search  for  potential  markers,  neurofilaments  appear  the  most 
promising, and future studies need to confirm the findings.
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